

UNIVERSIDADE ESTADUAL DE MONTES CLAROS

Jaciara Neves Sousa

Efeitos do extrato hidroalcoólico da folha de *Davilla elliptica* (Dilleniaceae) A.  
St.-Hil sobre parâmetros metabólicos de camundongos obesos induzidos por  
dieta

Montes Claros  
2019

Jaciara Neves Sousa

Efeitos do extrato hidroalcoólico da folha de *Davilla elliptica* (Dilleniaceae) A. St.-Hil sobre parâmetros metabólicos de camundongos obesos induzidos por dieta

Exame de defesa (Mestrado) apresentado ao Programa de Pós-graduação em Ciências em Saúde da Universidade Estadual de Montes Claros-Unimontes, como parte das exigências para a obtenção do título de Mestra em Ciências da Saúde.

Área de Concentração: Mecanismos e Aspectos Clínicos das doenças

Orientador: Prof. Dr. Sérgio Henrique Sousa Santos

Coorientadora: Profa. Dra. Valéria Mafra Cota

Montes Claros  
2019

S725e Sousa, Jaciara Neves.  
Efeitos do extrato hidroalcoólico da folha de *Davilla elliptica* (Dilleniaceae) A. St.-Hil sobre parâmetros metabólicos de camundongos obesos induzidos por dieta [manuscrito] / Jaciara Neves Sousa. – 2019.  
93f. : il.

Inclui bibliografia.  
Dissertação (mestrado) - Universidade Estadual de Montes Claros - Unimontes, Programa de Pós-Graduação em Ciências da Saúde/PPGCS, 2019.

Orientador: Prof. Dr. Sérgio Henrique Sousa Santos.  
Coorientadora: Profa. Dra. Valéria Mafra Cota.

1. Obesidade. 2. Tecido adiposo. 3. Planta medicinal. 4. *D. elíptica*. I. Santos, Sérgio Henrique Sousa. II. Cota, Valéria Mafra. III. Universidade Estadual de Montes Claros. III. Título.

## UNIVERSIDADE ESTADUAL DE MONTES CLAROS-UNIMONTES

Reitor(a): Antônio Alvimar Souza

Vice-reitor(a): Ilva Ruas de Abreu

Pró-reitor(a) de Pesquisa: Virgílio Mesquita Gomes

Coordenadoria de Acompanhamento de Projetos: Antônio Dimas Cardoso

Coordenadoria de Iniciação Científica: Sônia Ribeiro Arruda

Coordenadoria de Inovação Tecnológica: Dário Alves de Oliveira

Pró-reitor(a) de Pós-graduação: André Luiz Sena Guimarães

Coordenadoria de Pós-graduação Lato-sensu: Augusto Guilherme Silveira Dias

Coordenadoria de Pós-graduação Stricto-sensu: Maria de Fátima Rocha Maia

## PROGRAMA DE PÓS-GRADUAÇÃO EM CIÊNCIAS DA SAÚDE

Coordenador: Prof. Dr. Alfredo Mauricio Batista de Paula

Subcoordenadora: Prof. Dra. Marise Fagundes da Silveira



UNIVERSIDADE ESTADUAL DE MONTES CLAROS  
PROGRAMA DE PÓS-GRADUAÇÃO EM CIÊNCIAS DA SAÚDE



MESTRANDO(A): JACIARA NEVES SOUSA

TÍTULO DO TRABALHO: "Efeitos do extrato hidroalcoólico da folha de Davilla elliptica (Dilleniaceae) A. St.-Hil sobre parâmetros metabólicos de camundongos obesos induzidos por dieta"

ÁREA DE CONCENTRAÇÃO: Mecanismos e Aspectos Clínicos das Doenças

LINHA DE PESQUISA: Clínica, Diagnóstico e Terapêutica das Doenças

BANCA (TITULARES)





PROF. DR.SÉRGIO HERNIQUE SOUSA SANTOS- ORIENTADOR/PRESIDENTE

PROF<sup>a</sup>. DR<sup>a</sup>. VALÉRIA MAFRA COTA - COORIENTADORA

PROF. DR. LUIZ FERNANDO DE REZENDE

PROF<sup>a</sup>. DR<sup>a</sup>. FRANCINE SOUZA ALVES DA FONSECA

ASSINATURAS

BANCA (SUPLENTES)

PROF. DR. ANDRÉ LUIZ SENA GUIMARÃES

PROF. DR. JOÃO MARCUS OLIVEIRA ANDRADE

ASSINATURAS

APROVADA

REPROVADA

Hospital Universitário Clemente Farias – HUCF

<http://www.unimontes.br> / [ppgcs@unimontes.br](mailto:ppgcs@unimontes.br)

Telefone: (0xx38) 3224-8372 / Fax: (0xx38) 3224-8372

Av. Cula Mangabeira, 562, Santo Expedito, Montes Claros – MG, Brasil – Cep: 39401-001

Ao meu **DEUS**, que me fez uma pessoa nova durante este Mestrado, capaz de superar as dificuldades, muitas vezes imposta por mim mesma, sustentou-me e fez das minhas fraquezas a minha força.

## AGRADECIMENTOS

A **Deus**, agradeço pela coragem de facear as dificuldades criadas por mim mesma, pelas provações que me aperfeiçoam o raciocínio e me abrandam o coração. Toda honra e toda glória sejam dadas a Ti, Senhor;

Aos meus pais, **Jorlando e Laurentina**, por todo amor, apoio e incentivo, vocês são a razão de tudo o que faço na vida! Amo vocês de todo meu coração;

A minha irmã, **Janaína**, por sempre me acompanhar, madrugadas a fio, estudando, por estar ao meu lado e ser a melhor amiga sempre;

Ao professor orientador, **Sérgio**, por quem tenho uma profunda admiração, agradeço por toda dedicação, paciência e por ter sido tão bom comigo durante todos esses anos, obrigada pela confiança e por contribuir de forma imprescindível para a minha formação acadêmica, profissional e pessoal;

A minha coorientadora, **Valéria**, agradeço a solicitude em estar sempre presente, bem disposta a ajudar, você é um exemplo de ser humano e de profissional. Obrigada por contribuir de forma grandiosa com este Mestrado;

Aos colegas do Laboratório de Pesquisa em Saúde, pelo aprendizado diário e permanente. Apesar de pouco contato com alguns, foi um prazer estar com vocês: Lílian, Otávio, Dani Moreira, Dani Paola, Magda, Valéria, Renata, Daniel, Fábio, Bere, Handyara, Janaina, Natália, Luís Paulo, Victor, Felipe, Marcela, Erivelton, Sabrina, Eloá, Amanda Rodrigues, Amanda Souto, Amanda Lacerda, Deborah, Rogério, Emisael, Andreia e Marileide;

A amiga **Alanna**, por ter confiado em mim e me ensinando os cuidados necessários ao biotério, pela nossa amizade, confidências e risadas ao longo desses anos, muito obrigada Alanete, você foi muito importante para minha formação;

A amiga **Dani Freitas**, pela companhia nas intermináveis noites de escrita, sempre com bom humor, até mesmo quando o cansaço e o sono eram desmedidos;

Aos amigos, **Gabi, Pâmela, Celinha e Roni**, pelos bons tempos de convivência, pelos ensinamentos, pela amizade. Vocês foram pessoas maravilhosas que Deus colocou em minha vida;

Aos colegas do Mestrado Acadêmico (**Turma 01/2017**), agradeço pelo aprendizado e pelas oportunidades de crescimento intelectual e moral;

À funcionária da secretaria do PPGCS, **Do Carmo**, agradeço pela ajuda em momentos oportunos e necessários;

Aos camundongos **SWISS**, que tiveram as vidas extirpadas em prol do conhecimento científico;

À **UNIMONTES** que me permitiu ser parte de um todo que é esta Universidade, meu muito obrigada;

À **CAPES, CNPq e FAPEMIG** pelo incentivo e fomento à pesquisa;

Aos **amigos** de uma vida inteira, assim como aos amigos conquistados durante a caminhada: obrigada pela torcida e pelo suporte! A todos aqueles que contribuíram de alguma forma para esta conquista, muito obrigada;



“Não é o quanto fazemos, mas quanto de amor colocamos naquilo que fazemos. Não é o quanto damos, mas quanto de amor colocamos em dar”.

(Madre Teresa de Calcutá)

## RESUMO

A obesidade é caracterizada pelo acúmulo excessivo ou anormal de gordura corporal, causada pelo desequilíbrio entre o consumo e o dispêndio energético. O uso de plantas com fins medicinais, para o tratamento, cura e prevenção de doenças, é uma das mais antigas formas de prática medicinal utilizada pela humanidade. Evidências acumuladas revelam o uso tradicional da *Davilla elliptica* como adstringente tônico, laxativo e diurético. Esta espécie apresenta uma grande diversidade de substâncias do metabolismo secundário, como flavonoides, saponinas, esteroides, taninos, cumarinas e triterpenoides, e são descritas por seus efeitos anti-inflamatórios, antimicrobianos e gastroprotetores. Nessa perspectiva, no primeiro capítulo dessa dissertação, apresentamos uma revisão narrativa sobre a *D. elliptica*, e seus aspectos farmacológicos. Em seguida, avaliamos o potencial terapêutico do extrato hidroalcoólico de folhas da *D. elliptica* sobre parâmetros metabólicos de camundongos obesos induzidos por dieta. Para isso, oito grupos de camundongos *SWISS* foram utilizados no experimento: controle (dieta padrão), dieta padrão + EA (fração de acetato de etila), dieta padrão + HE (extrato hidroalcoólico das folhas de *D. elliptica*), dieta padrão + PL (pó da folha) e dieta hiperlipídica adicionada EA, HE e PL na dose de 0,26mg/kg/peso corporal, tratados por um período de quatro semanas. Durante o tratamento, foram avaliados peso corporal e ingestão alimentar. Ao fim do tratamento, testes de tolerância à glicose e sensibilidade à insulina foram realizados para avaliar o metabolismo glicêmico. Em seguida, os animais foram sacrificados por decapitação por guilhotina e amostras de sangue foram coletadas para análises bioquímicas da glicose, triglicérides e colesterol total. O estudo foi aprovado pelo Comitê de Ética e Pesquisa Experimental da Universidade Estadual de Montes Claros. Os resultados foram descritos em dois artigos. No primeiro, foram mostrados os efeitos terapêuticos e as propriedades biológicas da *D. elliptica*. Na estratégia de busca dos artigos, foi utilizado como descritor o termo “*Davilla elliptica*”, de maneira que foram recuperados artigos, anais de congresso, livros, teses e dissertações. No segundo artigo, os principais achados mostraram uma redução da adiposidade e do peso corporal em animais alimentados com dieta hiperlipídica, já os animais alimentados com dieta padrão demonstraram melhoras nos parâmetros bioquímicos. Este é o primeiro estudo a investigar o papel da *D. elliptica* sobre os parâmetros metabólicos da obesidade. Análises futuras serão realizadas para investigar por quais mecanismos e vias de sinalização a *D. elliptica* atua sobre a obesidade.

**Palavras-chave:** Obesidade. Tecido adiposo. Planta medicinal. *D. elliptica*.

## ABSTRACT

Obesity is a disease characterized by excessive accumulation of body fat caused by the imbalance between consumption and energy expenditure. The use of medicinal plants for the treatment, cure and prevention of diseases is one of the oldest forms of medicinal practice used by mankind. Cumulative evidence reveals the traditional use of *Davilla elliptica* as a tonic, laxative and diuretic astringent. This species exhibits a wide range of secondary metabolism substances such as flavonoids, saponins, steroids, tannins, coumarins and triterpenoids - described for their anti-inflammatory, antimicrobial and gastroprotective effects. In this perspective, in the first chapter, of this dissertation, we present a narrative review on *D. elliptica*, and their pharmacological aspects. Next, we evaluated the therapeutic potential of *D. elliptica* leaf hydroalcoholic extract on metabolic parameters of diet-induced obese mice. To this end, eight groups of *SWISS* mice were used in the experiment: control (standard diet); standard diet + EA (ethyl acetate fraction); standard diet + HE (hydroalcoholic extract of *D. elliptica* leaves); standard diet + PL (leaf powder) (0.26 mg/kg/body weight); control (high fat- diet); high fat- diet + EA; high fat- diet + HE; and high fat- diet + PL (0.26 mg/kg/body weight). The animals were treated for a period of four weeks. During the treatment, body weight and food intake were evaluated. At the end of treatment, glucose tolerance and insulin sensitivity tests were performed to assess glycemic metabolism. The animals were then sacrificed by guillotine decapitation and blood samples were collected for biochemical analyzes of glucose, triglycerides and total cholesterol. The study was approved by the Committee of Ethics and Experimental Research of the State University of Montes Claros. The results were described in two articles. The first showed the therapeutic effects and biological properties of *D. elliptica*. In the article search strategy, the term "*Davilla elliptica*" was used as descriptor, and literature sources consisted of articles, congress proceedings, books, theses and dissertations. In the second article, the main findings showed a reduction of adiposity and body weight in animals fed a high fat- diet, and animals fed a standard diet showed improvements in biochemical parameters. This is the first study to investigate the role of *D. elliptica* on the metabolic parameters of obesity. Future analyzes will be carried out to investigate by which mechanisms and signaling pathways *D. elliptica* acts on obesity.

**Key words:** Obesity. Adipose tissue. Medicinal plant. *D. elliptica*.

## LISTA DE ILUSTRAÇÕES

Figura 1- Expansão do tecido adiposo.....	14
Figura 2 – Locais anatômicos de deposição de adipócitos. ....	15

## LISTA DE TABELAS

Tabela 1 Descrição das principais espécies do gênero <i>Davilla</i> e a relação de compostos químicos com sua atividade biológica.....	19
--	----

## LISTA DE ABREVIATURAS E SIGLAS

OMS	Organização mundial de saúde
TAB	Tecido adiposo branco
IL-1 $\beta$	Interleucina 1 beta
IL-6	Interleucina 6
TNF- $\alpha$	Fator de necrose tumoral alfa
LDL	Lipoproteína de baixa densidade
HDL	Lipoproteína de alta densidade
TAM	Tecido adiposo marrom
UCP1	Proteína desacopladora 1
PNPIC	Política Nacional de Práticas Integrativas e Complementares
SUS	Sistema único de saúde

## SUMÁRIO

1 INTRODUÇÃO .....	14
1.1 Obesidade.....	14
1.2 Cerrado.....	16
1.3 Plantas Medicinais.....	17
1.4 Gênero <i>Davilla</i> .....	18
2 OBJETIVOS .....	20
2.1 Objetivo Geral .....	20
2.2 Objetivos Específicos .....	20
5 PRODUTOS .....	21
5.1 Artigo 1: <i>Davilla elliptica (Dilleniaceae) A. St.-Hil. medicinal, pharmacological and phytochemical aspects: a review</i> .....	22
5.2 Artigo 2: <i>Effects of oral treatment with Davilla elliptica leaf extract on diet-induced obese mice</i> .....	52
6 CONCLUSÕES.....	70
REFERÊNCIAS .....	71
ANEXOS .....	74

# 1 INTRODUÇÃO


## 1.1 Obesidade

A obesidade está comumente associada a um aumento significativo da mortalidade e da redução da expectativa de vida de 5 a 10 anos (1-3). Caracterizada pelo acúmulo anormal de gordura corporal, a obesidade resulta do desequilíbrio entre o consumo e o gasto de energia (4). Segundo dados da Organização Mundial de Saúde (OMS), é uma epidemia global, um crescente problema de saúde pública (5).

Durante a obesidade, mudanças fenotípicas ocorrem no tecido adiposo, subsequente ao processo de inflamação (1, 6). O tecido adiposo branco (TAB) é um órgão multifatorial capaz de alterar suas dimensões, tamanho e estado inflamatório, em resposta ao estado nutricional (7-9).

A expansão anormal do tecido adiposo branco é responsável por provocar alterações na composição extracelular, vascularização, tamanho e estado inflamatório das células imunes infiltradas, aumentando níveis de ácidos graxos livres circulantes e fatores pró-inflamatórios como: fator de necrose tumoral alfa (TNF- $\alpha$ ) e interleucinas, IL-1 $\beta$ , IL-6 (9, 10).

A obesidade é ainda associada à um quadro de dislipidemia, com aumento nos níveis da lipoproteína de baixa densidade (LDL), diminuição da lipoproteína de alta densidade (HDL) além de níveis elevados de triglicérides (1, 8) (Fig. 1).



**Figura 1:** Expansão do tecido adiposo branco sobre condições fisiológicas distintas. a) Durante a expansão do TAB saudável, o tecido está em um estado anti-inflamatório, há




vasculatura suficiente para suportar a expansão e os adipócitos sofrem hiperplasia. b) TAB não saudável abriga adipócitos hipertróficos aumentados e um estado elevado de inflamação: macrófagos M1 pró-inflamatórios infiltrados. A formação de nova vasculatura ocorre para suportar o crescimento de TAB. Estes eventos contribuem para o desenvolvimento da resistência à insulina. Adaptado de Kusminski CM, Bickel PE, Scherer PE, 2016 (7).

Em mamíferos, além do tecido adiposo branco encontra-se o tecido adiposo marrom (TAM) que atua tanto no armazenamento de nutrientes como lipídios quanto dissipando energia em forma de calor em um processo chamado termogênese (11).

Os adipócitos castanhos são caracterizados por uma estrutura de gotículas lipídicas, multiloculares, com alto conteúdo de mitocôndrias e produção da proteína desacopladora 1 (UCP1) que está localizada na membrana mitocondrial interna (11).

A ativação de TAM está positivamente correlacionada com a quantidade desse tecido, o seu estado de ativação e fatores ambientais, tais como baixas temperaturas. Em humanos, a exposição repetida ao frio leva ao aumento da atividade do TAM. Esse aumento na atividade do TAM também tem sido fortemente correlacionado com aumentos induzidos pelo frio no gasto de energia pela termogênese sem tremores (12-17) (Fig. 2).



**Figura 2:** Locais anatômicos de deposição de adipócitos marrons, brancos e beges em camundongos e humanos. a) Em camundongos, o tecido adiposo marrom interescapular contém adipócitos marrons clássicos. O tecido adiposo branco do epidídimo contém

predominantemente adipócitos brancos. O tecido adiposo branco inguinal contém uma população mista de adipócitos brancos e beges, cujas proporções dependem do meio ambiente e dieta. b) Nos adultos humanos, a gordura subcutânea possui características do tecido adiposo branco clássico. O tecido adiposo marrom supraclavicular é composto por adipócitos brancos, marrons e beges, enquanto no marrom clássico o tecido adiposo pode ser encontrado no fundo do pescoço, próximo ao tecido muscular. Adaptado de Bartelt A, & Heeren J, 2014 (11).

Como alternativa para o tratamento e prevenção da obesidade, espécies de plantas do Cerrado têm sido alvo de interesse, alguns fatores poderiam explicar o interesse na pesquisa desse campo, a busca por terapias menos agressivas, resgatando o conhecimento tradicional da população e os avanços ocorridos na área da pesquisa científica (25).

## 1. 2 Cerrado

O bioma brasileiro Cerrado é a flora que apresenta maior riqueza de todas as Savanas do mundo. É um reservatório de potenciais espécies com atividades terapêuticas. Com mais de 10.000 espécies de plantas das quais 4.000 são endêmicas, o Cerrado é um *hotspot* global de biodiversidade (44). Embora seja fundamental para a conservação de espécies e para o suprimento de serviços ecossistêmicos, o Cerrado perdeu 88 milhões de hectares – Mha (46%) de sua cobertura vegetal nativa e apenas 19,8% permanecem inalterados (18).

O Cerrado compreende um tipo de vegetação associado a condições ecológicas especiais em que a vegetação de Savana domina, mas não é necessariamente exclusiva, sendo intercalada com matas ciliares ou matas de galeria, trechos de florestas semidecídua, ambientes úmidos, pântano e / ou pântanos (19, 20). No entanto, o cerrado *sensu lato* inclui uma variedade de fisionomias de campo limpo, campo sujo, cerrado *sensu stricto* e “cerradão” (19). Constitui uma formação florestal, em que a densidade de indivíduos lenhosos (árvores e arbustos) é uma das variáveis mais evidentes (21).

O Rio Pandeiros, localizado no interior do Norte de Minas Gerais, inicialmente chamado de “*Sertão*” por Auguste de Saint-Hilaire, comporta uma flora abundante em espécies com potenciais farmacológicos. Nesse contexto, a pesquisa histórica explana uma rica fonte de informações sobre o uso da biodiversidade brasileira. Mügge e colaboradores (2016) propõem que os frutos de algumas espécies nativas do Cerrado, como *Xylopia aromática*, *Davilla rugosa* e *Stachytarpheta jamaicensis*, possuem um alto valor econômico e são utilizadas para produzir renda às populações do interior de Minas Gerais. As espécies

*Davilla elliptica*, *Davilla papyracea* e *Davilla angustifolia* pertencentes ao gênero *Davilla* também foram registradas no Cerrado mineiro (22).

O Cerrado é detentor de expressivo potencial de plantas com fins terapêuticos, porém requer especial atenção, novas pesquisas e incentivos, objetivando o uso racional pela população (23).

### 1.3 Plantas medicinais

Plantas medicinais são utilizadas na medicina popular como medicamentos tradicionais e fonte de tratamento há milhares de anos (24).

O uso de plantas com fins medicinais, para o tratamento, cura e prevenção de doenças é uma das mais antigas formas de prática medicinal utilizada pela humanidade. Na década de 1990, a Organização Mundial de Saúde (OMS) notificou que 65-80% da população dos países em desenvolvimento dependiam principalmente das plantas como única forma de acesso aos cuidados básicos de saúde, sendo que sua utilização tem sido crescente em países desenvolvidos (25).

Diante do exposto, o termo “planta medicinal” é definido pela OMS como sendo “todo ou qualquer material vegetal que possui, em um ou mais órgãos vegetais, substâncias que podem ser utilizadas com fins terapêuticos ou que sejam precursores de fármacos semissintéticos”. Sendo relatado que as plantas do Cerrado são fonte de compostos de alto interesse biotecnológico, com aplicações nas indústrias alimentícias, cosméticas e farmacêuticas (26).

A utilização de plantas medicinais, como recurso terapêutico alternativo ou adicional, tem aumentado consideravelmente e têm sido utilizadas no tratamento de vários problemas de saúde e este vasto consumo tem sido sob a forma de pó, chás, óleos ou formas associadas (27).

No Brasil, a Política Nacional de Práticas Integrativas e Complementares (PNPIC), aprovada em 2006, segue as recomendações preconizadas pela OMS e se propõe a normatizar, adequar e implantar o uso de plantas medicinais como fitoterápicos no Sistema Único de Saúde (SUS), com o objetivo de reduzir custos, aumentar as formas de terapias e resgatar os conhecimentos tradicionais da população (28).

Em 2010, foi criada a Farmácia Viva, responsável por todo o processamento das plantas medicinais desde o cultivo até a comercialização. Diversos municípios brasileiros estão inseridos nesse programa. A secretaria do Estado de Saúde de Minas Gerais percebeu a

necessidade de conhecer as diferentes atividades praticadas para tratamentos realizados na rede pública de saúde do estado a partir da Resolução nº 1.885, de 27 de maio de 2009 e implantou estratégias preconizadas pela PNPIC no SUS/MG com o intuito de melhorar a qualidade de vida da população, por integração multidisciplinar entre a cultura popular e a ciência (28).

O uso das plantas medicinais cresceu substancialmente, estes produtos naturais continuam a ser um complemento terapêutico, ou mesmo a base, para o tratamento de doenças (29).

#### 1.4 Gênero *Davilla*

O gênero *Davilla* é definido, segundo Kubitzki (1971), por apresentar margens flexionadas, não alatas, das sépalas mais internas, sobrepostas pelas sépalas internas adjacentes (30). É amplamente distribuído e tem como outros exemplos de espécie a *D. kunthii*, *D. nitida* (Vahl.) Kubitzki, *D. rugosa* (Poir.), com distribuição geográfica no Neotrópico. Diferenciando-se das outras espécies do gênero, que são ocorrentes no cerrado, a *D. flexuosa* é geograficamente encontrada em áreas com solos arenosos, como os existentes nas áreas da planície quaternária litorânea, comumente denominada Restinga (31, 32). A classe de compostos comumente encontrada em todos estes gêneros é a classe de flavonoides, conforme mostrado na Tabela 1.

Estudos demonstram que algumas espécies do gênero *Davilla*, como *D. rugosa*, *D. kunthii*, *D. nítida*, apresentam propriedades adaptogênicas, ansiolíticas, antimicrobianas, antioxidantes e antiulcerativas (33, 34). Ensaios *in vivo* e *in vitro* evidenciam que os extratos de *D. nitida* e *D. kunthii* promovem uma inibição de bactérias multirresistentes das espécies *Pseudomonas spp.*, *Enterobacter spp.*, *Staphylococcus aureus*, *Streptococcus pneumoniae*, *Staphylococcus saprophyticus*, bem como, levedura *Candida albicans*, respectivamente (35, 36). Adicionalmente, atividades adaptogênicas foram ainda observadas para a espécie *D. rugosa*, com efeito protetor contra úlceras em modelos experimentais *in vivo* (33, 34).

Diante da importância da espécie *Davilla elliptica* e seus potenciais efeitos farmacológicos já descritos, é de fundamental importância a análise do seu potencial anti-inflamatório sobre a obesidade e suas comorbidades associadas, de forma que a *D. elliptica* poderá contribuir para a identificação de novos alvos terapêuticos capazes de atuar simultaneamente nos fatores de risco desencadeantes da doença, permitindo um melhor prognóstico e tratamento de doenças relacionadas à obesidade.

Tabela 1. Descrição das principais espécies do gênero *Davilla* e a relação de compostos químicos com sua atividade biológica.

Espécie	Parte vegetativa	Fração	Substâncias	Atividade biológica	Autor
<i>D. flexuosa</i> St. Hill.	Folhas	Hexano; acetato de etila	Miricetina; quercetina miricetina 3-ramnosídeo; miricetina 3'-ramnosídeo $\alpha$ -tocoferol	Não descrito	David <i>et al.</i> , (1996) (37)
		Hidroalcoólico; clorofórmio; clorofórmio/acetato de etila; acetato de etila; acetato de etila/ etanol; etanol; etanol/água.		Efeitos estimulantes; Atividade intestinal; Atividade motora e ansiolítica.	Guaraldo <i>et al.</i> , (2000) (38)
<i>D. rugosa</i> Poiret	Hastes	Hidroalcoólico; clorofórmio; clorofórmio/acetato de etila; acetato de etila; acetato de etila/etanol; etanol; etanol/água.	Saponinas; flavonoides e mucilagem	Anti-úlceras gástricas.	Guaraldo, L.; Sertie, J. A. A.; Bacchi, E. M. (2001) (39)
		Hidrometanólico; hexano; clorofórmio; acetato de etila	Friedelina; sitostenona ácido betulínico; narigenina e quercetina 4'-O-metil taxifolina	Não descrito	David <i>et al.</i> , (2006) (40)
	Partes aéreas	Hidroalcoólico	Alcaloides; flavonoides; saponinas; polifenóis/taninos; cumarinas; lignanas	Atividade adaptogênica; Atividade antioxidante; Efeito moderado antiúlcera;	Mendes, F. R.; Tabach, R.; Carlini, E. A. (2007) (41)
<i>D. kunthii</i> A. St. -Hil.	Folhas	Etanólico		Atividade antimicrobiana e antioxidante	Nascimento <i>et al.</i> , (2016) (42)
<i>Davilla nitida</i> (Vahl) <i>Kubitzki</i>	Casca	Etanólico	Terpenos Flavonoides Taninos	Atividade antibacteriana	Perim <i>et al.</i> , (2018) (43)

## 2 OBJETIVOS

### 2.1 Objetivo geral

Avaliar o potencial do extrato hidroalcoólico das folhas da *Davilla elliptica* sobre parâmetros metabólicos de camundongos obesos submetidos a uma dieta hiperlipídica.

### 2.2 Objetivos específicos

2.2.1 Caracterizar as classes de compostos presentes nas folhas da espécie *D. elliptica*.

2.2.2 Avaliar o efeito da administração do extrato hidroalcoólico e das frações das folhas de *Davilla elliptica*, nos diferentes grupos de estudo.

2.2.3 Avaliar a regulação glicêmica por meio de testes de sensibilidade insulínica e tolerância à glicose.

2.2.4 Mensurar os níveis plasmáticos lipídicos, dosando especificamente os níveis de triglicérides e colesterol total.

2.2.5 Mensurar os níveis de glicose sanguínea.

## 5 PRODUTOS

5.1 Produto 1: *Davilla elliptica* (Dilleniaceae) A. St.-Hil. medicinal, pharmacological and phytochemical aspects: a review, formatado segundo as normas para publicação do periódico Journal of Ethnopharmacology.

5.2 Produto 2: *Effects of oral treatment with Davilla elliptica leaf extract on diet-induced obese mice*, formatado segundo as normas para publicação do periódico Journal of Ethnopharmacology.

## 5.1 PRODUTO 1

***Davilla elliptica* (Dilleniaceae) A. St.-Hil. medicinal, pharmacological and phytochemical aspects: a review**

Jaciara Neves Sousa<sup>1</sup>, Victor Hugo Dantas Guimarães<sup>1</sup>, Deborah de Farias Lelis<sup>1</sup>, Alanna Fernandes Paraiso<sup>1,2</sup>, Valéria Mafra Cota<sup>3</sup>, Sérgio Henrique Sousa Santos<sup>1,4</sup>

<sup>1</sup>*Laboratory of Health Science, Postgraduate Program in Health Science, Universidade Estadual de Montes Claros (Unimontes), Minas Gerais, Brazil.*

<sup>2</sup>*Institute Santo Agostinho, Montes Claros, Minas Gerais, Brazil.*

<sup>3</sup>*Federal Institute of Education, Science and Technology of the North of Minas Gerais (IFNMG), Januária, Minas Gerais, Brazil*

<sup>4</sup>*Institute of Agricultural Sciences (ICA), Food Engineering, Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, Minas Gerais, Brazil.*

\* Correspondence to Sérgio Henrique Sousa Santos, Institute of Agricultural Sciences. Food Engineering College, Universidade Federal de Minas Gerais (UFMG); Avenida Universitária, 1.000 – Universitário, 39.404-547, Montes Claros, MG, Brazil. E-mail: sergiosousas@hotmail.com.

**ABSTRACT**

*Ethnopharmacological relevance:* *Davilla elliptica* (Dilleniaceae) is a shrub that occurs naturally in the Brazilian Savannah (Cerrado). *D. elliptica* and its relative specie *D. rugosa* have been traditionally used in Brazilian folk medicine on tea preparing, infusions, and decoctions from leaves and roots for gastritis, ulcers and diarrhea treatment.

*Aims:* The present study aimed to provide a comprehensive review on ethnopharmacological uses, botanical aspects of *Davilla elliptica*, as well as research findings about phytochemistry characterization, *in vivo* and *in vitro* pharmacological studies using extracts, fractions and/or isolated compounds that support its potential therapeutic to treat several human diseases.

*Materials and methods:* The relevant and updated reports about *D. elliptica* were retrieved from the scientific databases Web of Science, Google Scholar, Scopus, SciFinder, PubMed,




SciELO, and ScienceDirect. Additional information derived from un-published resources and other literature sources such as books, Ph.D. and MSc thesis was also considered after a critical review.

*Results:* Ethnopharmacological reports of *Davilla elliptica* revealed the use of infusions from roots with astringent, tonic and purgative effects, whereas leaves have been used as anti-inflammatory, anti-ulcerative, and to treat diarrhea and gastric disorders. Also, fresh leaves have been used in baths to treat swellings. Phytochemical studies has led to the isolation of relevant secondary compounds such as terpenes, flavonoids derived from quercetins and myricetins, a higher concentration of tannins, and others. *In vitro* assays using crude extracts and/or isolated fractions of leaves and roots from *D. elliptica* have evidenced antibacterial, antioxidants and antitumoral effects, while *in vivo* studies have proven antinociceptive or gastroprotective effects from hydroalcoholic extract. Concerning toxicological effects of extracts and fractions from *D. elliptica*, one report showed slight mutagenicity potential in *Salmonella*, while no significant genotoxic effect was detected in mice. However, further studies with long-term and repeated administration and/or the use of higher concentration of extracts are needed to ensure the safety of the therapeutic use of *D. elliptica*.

*Conclusion:* This review summarizes current knowledge about ethnomedicinal use of *D. elliptica*, provides relevant information about its botanical aspects, current taxonomy and distribution and highlights main findings from research studies related to its phytochemical characterization, toxicology and efficacy of crude extracts, fractions and isolated compounds of *D. elliptica* with relation to their therapeutic potential. We found scientific evidences that corroborates the popular use of *D. elliptica* to treat several human diseases, particularly those related to gastric disorders and inflammation. However, these studies were preliminary, based on *in vivo* studies using animal models, which requires further investigation in preclinical and clinical trials to confirm these therapeutic effects. Also, studies underlying molecular mechanisms involved with mechanism of action of the bioactive components and tests using different fractions or isolated compounds are still lacking, open great opportunities for future studies.

## Graphic abstract



**Keywords:** ethnomedicine; phytochemistry; inflammation; antioxidant; antimicrobial.

### Abbreviations

COX-1, Cyclooxygenase-1; GST, Glutathione S-transferase; H<sub>2</sub>O<sub>2</sub>, Hydrogen peroxide; IC, inhibitory concentration; iNOS, Inducible nitric oxide synthase; LD, lethal dose; LPS, Lipopolysaccharides; MIC, Minimal inhibitory concentration; MMP-9, Metallo-9-matrix proteinases; MTT, 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl-2H-tetrazolium bromide; NF-κB, Factor nuclear kappa B; NO, Nitric oxide; NO<sub>2</sub>, Nitrogen dioxide; SOD, Superoxide dismutase; TNF-α: Tumor necrosis factor alpha; WHO, World Health Organization.

### Chemical compounds studied in this article

(-)-epicatechin (PubChem CID: 72276); gallic acid (PubChem CID: 370); kaempferol (PubChem CID: 5280863); quercetin (PubChem CID: 5280343); isoquercetin ou quercetin-3-glucoside (PubChem CID: 5280804); quercitrin ou quercetin-3-rhamnoside (PubChem CID: 5280459); hyperoside ou quercetin-3-O-β-D-galactopyranoside (PubChem CID: 5281643); guajavarin ou quercetin-3-O-α-L-arabinopyranoside (PubChem CID: 5481224); quercetin-3-

O- $\alpha$ -L-rhamnopyranoside (PubChem CID: 40486293); myricetin (PubChem CID: 5281672); myricetin-3-arabinoside (PubChem CID: 21672568) myricitrin ou myricetin-3-O- $\alpha$ -L-rhamnopyranoside (PubChem CID: 5281673); myricetin 3-galactoside ou myricetin-3-O- $\beta$ -D-galactopyranoside (PubChem CID: 5491408); myricetin-3-O- $\beta$ -D-glucopyranoside (PubChem CID: 5318606); myricetin-3-O-(2''-O-galloyl)- $\alpha$ -L-rhamnopyranoside (PubChem CID: 5316590); 3-O-galloylmucic acid ou myricetin-3-O-(3''-O-galloyl)- $\alpha$ -L-rhamnopyranoside (PubChem CID: 101248998); myricetin-3-O-(2''-O-galloyl)- $\beta$ -D-galactopyranoside (PubChem CID: 101114351); (6S)-vomifoliol ou (6S,7E)-6,9-dihydroxy-4,7-megastigmadien-3-one (PubChem CID: 12444927); rutin (PubChem CID: 5280805).

## 1. Introduction

Natural products derived from plants have been considered a primary source of chemical diversity with therapeutic purposes by traditional medicine and have prompted the development of many drugs over the past century (Veeresham, Ciddi, 2012). Throughout the history, the folk use of plants has been well documented. Plant extracts have been used in the form of natural remedies such as teas, potions and oils with many of these bioactive compounds still being unidentified (Dias, Urban and Roessner, 2012; Gurib-Fakim, 2006). According to the World Health Organization (WHO), the plant-based traditional medicines have been widely disseminated worldwide, especially in developing countries where population commonly use herbs for primary health care (Akerele, O., 1993). It has been estimated that approximately 80% of 122 plant derived drugs developed exert similar or related effects based on the original ethnopharmacological knowledge (Fabricant and Norman, 2001). However, nearly 10% of the total biodiversity of higher plant species have been systematically explored (Cragg and Newman, 2005), open a wide opportunity to the discovery of new drug leads using plants as source, especially in Brazil, that has one of the richest flora worldwide.

In Brazil, The Brazilian Savannah, also known as Cerrado, has a high biodiversity, with approximately 10.000 plant species of which 4.000 are endemics, which characterize this biome as a hotspot (Myers et al., 2000). From these plant species stands out the medicinal plants. Among those, *Davilla elliptica* used in popular medicine for the treatment and prevention of some diseases, with proven pharmacological effects. Furthermore, this species presents important molecules with evidenced biological activities.

In this sense, this study presents a comprehensive review about the therapeutic potential of *Davilla elliptica*, starting from its geographic distribution, botanical

characterization and the current knowledge about its ethnomedicinal use. Following, we summarized the relevant research findings related to its phytochemical characterization, and scientific evidences supported by *in vitro* and *in vivo* experiments which corroborate the bioactive effects attributed to *D. elliptica* in traditional practices and other bioactive effects recently reported. Finally, discussions for directing future research were also proposed.


## 2. Materials and methods

Data on the *Davilla elliptica* botanical, and phytochemical description, and traditional and pharmacological use, published up to November 2018, were retrieved from the scientific literature in the following databases: Web of Science, Google Scholar, PubMed, Scielo, and ScienceDirect, in addition to the universities repositories that contain thesis and congress presentations. The term “*Davilla elliptica*” was used as a descriptor. The data was selected after a critical paired reading of the main findings to ensure more reliability of the data. The scientific names and botanical descriptions were validated in the following websites: [www.theplantlist.org](http://www.theplantlist.org) and [floradobrasil.jbrj.gov.br/reflora](http://floradobrasil.jbrj.gov.br/reflora). The molecules illustrations were carried out in the ChemDraw software (version 12.0), while the scheme pictures were created by the authors with the resources available in the [smart.servier.com](http://smart.servier.com) website. Photos of the studied species were accessed from the author’s personal archives. The data recovery and molecules registry were assessed at [pubchem.ncbi.nlm.nih.gov](http://pubchem.ncbi.nlm.nih.gov).

## 3. Botanical description and distribution Phenotypic characterization

*Dilleniaceae* is a family of plants with 14 genders, which comprise about 500 species with different arboreal, shrub and liana habits. Among them is the *Davilla* genus, with 20 species widely distributed in neotropical regions, being found in the central Savannah in Brazil. Within these species is *Davilla elliptica* A. St.-Hil, popularly known as “*lixeirinha*”, “*lixeira*”, “*bugre*”, “*sambaibinha*”, “*muricizinho*”, “*cipó-caboclo*”, “*cipó-de-carijó*”, “*pau-de-bugre*” and “*lixinha*”. The name “*elliptica*” is derived from the elliptical morphological aspect of their leaves, which have sinuous and slightly serrated edges, rough on the adaxial surface and hairy in the abaxial surface (Bustamante et al., 2004; Horn, 2009; Jácome et al., 2010; Santos and Ferreira, 2012). It has shrub and sub-bush habits, with ramifications of 0.6 cm up to 3 m in height, as shown in Figure 1. A number of idioblasts and a high mucilage content have also been reported to this species, and these characteristics were responsible for distinguishing *D. elliptica* from its relative species *D. rugosa* (Jácome et al., 2010).

This species to *Davilla elliptica* is characterized by phytochemical compounds presence, such as myricetin and quercetin rhamnoside. The specific name, *D. elliptica*, refers to the leaf of elliptical ambit a characteristic present in most of the species of the genus *Davilla* (Gurni and Kubitzki, 1981; Horn, 2009).



**Figure. 1** Phenotypic characteristics of *D. elliptica* showing young shrub (A), leaves (B) and mature fruits e ripe and dry fruits (C).

Regarding the *D. elliptica* vegetative development varies, it presents variations according to the environment: from evergreen, with continuous growth and brevideciduous behavior in which is inserted, justifying the differences found in the literature. A study by Silvério and Lenza (2010) evidenced an evergreen, with continuous growth and brevideciduous behavior, while a seasonal and deciduous growth was also reported by others (Lenza and Klink, 2006). In contrast, Lenza and Klink (2006) reported this species also as evergreen, but with seasonal and deciduous growth. Buds also occur in the dry season and may be less frequent in rainy conditions (Lenza and Klink, 2006; Silvério and Lenza, 2010). Leaf senescence occurs between September and October, when the dry season ends. During this period, the Budding occurs in dry season and may be less frequent in rainy conditions, whereas leaf senescence occurs at the end of this period (Lenza and Klink, 2006; Silvério and Lenza, 2010). After that, plants remain without leaves for approximately two weeks. The

same variations observed for the leaves were verified in the flowers, which arise in low-temperature months (17 to 18 °C), between January and May. The fruiting, on the other hand, occurs in the dry season, indicating that the species has mechanisms to overcome water stress (Gurni and Kubitzki, 1981; Horn, 2009). Fruit maturation occurs mainly during rainy periods and can be seen in the dry season. Seed dispersal occurs through the dry and rainy period.

The environmental variations in which the species is distributed impact directly in the anatomy, interfering in the height, fruit biomass, and leaves width and length. Regarding plant height, the individuals found in Veredas regions are higher, as well as with higher population density and flowering anticipation as compared to the Cerrado environment, where leaves length and width are higher. Regarding the fruits number, no significant differences were evidenced between the observed phytophysiognomies (Santos and Ferreira, 2012; Rocha Filho et al., 2006).

Concerning its distribution, studies have been shown that *D. elliptica* is an endemic shrub vegetation widely distributed at the Cerrado biome that occurs along a latitudinal gradient of about 1500 km, being found in areas such as cerrado *stricto sensu*, savannah and rupestrian field. In general, the environmental conditions of the cerrado are favorable for the occurrence of the species of the family Dilleniaceae, and *D. elliptica* is among the main representatives species both in frequency and in abundance. Besides of cerrado, *D. elliptica* is also found in the Chaco of Bolivia, with an estimated occurrence of more than 20,000 km<sup>2</sup> in a fragmented area concomitantly with agricultural crops such as soybean (Pereira, 2014).

Jácome et al. (2010) demonstrated for the first time in their studies an important pharmacognostic characteristic of the species, which presents increased idioblasts number followed by a high mucilage content, being these characteristics responsible for distinguishing *D. elliptica* from its relative species *D. rugosa* (Jácome et al., 2010).

#### **4. Fruits and seeds production**

The *D. elliptica* produces fruits and flowers protected by two synaparc capsules, which remain closed during maturation and exposes the flower in the pollination period. After the ovary fecundation, the synaparc capsules are closed until the end of the seeds maturation period. Each fruit produces a maximum of two seeds (Iubatã P. Faria et al. 2003).

In a study carried out in areas of the Cerrado *stricto sensu* and rupestrian fields, the proportion of intact seeds was 66% in the rupestrian fields and 29% in the Cerrado. This species is responsible for 32% of the seeds aborted in these two areas. Based on these findings, we conclude that the seeds abortion is the main determinant factor for the

development deficit of this plant in a few Cerrado regions, although the flowers predation rates in the rupestrian field and Cerrado *stricto sensu* correspond to 31% and 3%, respectively. Lepidoptera and Coleoptera larvae represent the main species responsible for the *D. elliptica* herbivorism (Iubatã P. Faria et al. 2003).

## 5. Distribution

The *D. elliptica* distribution in the Cerrado biome evidenced that this species is an endemic bush of shrub vegetation that occurs along a latitudinal gradient of approximately 1500 km, as the Cerrado *stricto sensu*, Savannah, and rupestrian field. The *D. elliptica*, with a wide distribution, is among the main Cerrado representatives, both in frequency and abundance. In general, the Cerrado environmental conditions are favorable to the occurrence of species from the *Dilleniaceae* family (Pereira, 2014).

Therefore, this species was collected in several disturbed environments, allowing it to be included in the low-risk species classification according to the International Union for Conservation of Nature criteria (Fraga, 2012).

Due to environmental factors such as population growth or competitor's interactions, the absence of this species can be observed in small geographic areas that could be favorable to its development. Therefore, it is verified that *D. elliptica* occurs in isolated areas, indicating that its dispersion is not a limiting factor (Pereira, 2014).

## 6. Population dynamics

Studies performed by Aquino et al. 2007 in areas of the Cerrado, demonstrated that specimens of *D. elliptica* presented an accentuated decrease in density and baseline area from between 1995 and 2002 when a high mortality rate was registered for this species. However, the seedlings recruitment registered in the *D. elliptica* vegetal community reached 12% year, opposing the high mortality rates. Felfili (1995) explained these findings by reporting that abundant species in the gallery forests are subjected to increased mortality and recruitment rates (Aquino et al., 2007; Felfili, 1995).

In this context, it is possible to observe that during the dry season, the occurrence of fires is frequent. The fire is responsible for altering the structure, flower composition, and plants recruitment, leading to a decreased trees density, thus changing the vegetal composition (Medeiros and Miranda, 2005; Felfili et al., 2000; Woods, 1989).


Studies report that *D. elliptica* is in great number in all Cerrado areas hit by fire. In the community dynamics, this species is responsible for recruiting individuals in 4.8%, despite being more sensitive to mortality by fires, totalizing 16.5% of dead individuals. In contrast,



this species presents high abundance in natural regeneration, with a relative density greater than or equal to 1, evidencing its potential to undergo intervention through a sustainable management regime (Barreira et al. 2002; Fiedler et al., 2004; Ribeiro et al., 2012).

### 7. Ethnopharmacological studies

In popular medicine, *D. elliptica* is widely disseminated by its medicinal use applications, as shown in Figure 2. Leaves have been used in the preparation of teas to treat gastric, inflammation, diarrhea and ulcer pain whereas fresh leaves have been used in baths to treat lymph nodes and testicular swellings. Roots infusion have been employed as tonic and laxative astringent. Other properties have been reported in ethnomedicinal practices such as its general use as , sedative, diuretic, contraceptive, antiseptic, and in the treatment of hemorrhoids, hematomas and hernia (Azevedo et al., 2007; Bonacorsi et al., 2013; Campos et al., 2013; Kushima et al., 2009; Michelin et al., 2005; Rodrigues and Carvalho, 2001). Aphrodisiac, healing and emollient properties were also reported previously, but in this study *D. elliptica*, *D. brasiliiana*, *D. cearensis* and other species were depicted as synonyms of *D. rugosa*, which makes it difficult to know from which species of *Davilla* these properties were attributed. However, more recently, a comprehensive phylogenetic study confirmed that these species are distinct each others, and a taxonomic revision of *Dilleniaceae* family was proposed (Fraga et al., 2012).



**Figure 2.** Effects ethnobotanical observed in popular medicine from different parts of *Davilla elliptica* in the treatment of diseases.



Additionally, Mendes and contributors reported other *D. elliptica* properties, including healing, emollient and aphrodisiac. However, the authors considered *D. elliptica*, *D. brasiliiana*, and *D. cearensis*, among other species as synonyms of *D. rugosa*. However, Fraga (2012) presented a phylogenetic classification and taxonomic review of the *Davilla* Vand. (Dilleniaceae), reporting the distribution, etymology, taxonomy, typification and characterizing species of the genus, as distinct species (Mendes et al., 2005; Fraga, 2012).


## 8. Phytochemistry

Phytochemical studies have been reported deidentified important compounds classes in *D. elliptica*, such as triterpenes, steroids, catechins, flavonoids, saponins, phenolic acid derivatives, coumarins, condensed tannins and tannins, the latter being in higher concentrations (Carlos et al., 2005; Soares et al., 2005). Also, phytochemical characterization using high-performance liquid chromatography, gas chromatography coupled to mass spectrometry, confirmed by certified standards or the nuclear magnetic resonance technique were able to identify compounds such as epicatechin, gallic acid, kaempferol, quercetin derivatives, myricetin derivatives, and rutin (Biso et al., 2008). Analyzes have demonstrated compounds such as epicatechin, gallic acid, kaempferol, quercetin derivatives, myricetin derivatives, and rutin, as detailed in Figure 3 (Biso et al., 2008; Campos et al., 2013; Kushima et al., 2009; Azevedo et al., 2015; Rinaldo et al., 2006; Rodrigues et al., 2008). These findings showed that myricetin-3-O- $\alpha$ -L-rhamnopyranoside was reported as the main flavonoid present in this species (Kushima et al., 2009). As expected, seasonal variations were found to have a significant influence on the presence of secondary metabolites, where the content of flavonoids and tannins the rainy season, in an analysis of ten grams of dry leaf, quantified in 0.91% and 7.20%, respectively. On the other hand, analyzes with leaf samples collected during the dry period presented a total flavonoid and tannin content of 1.20% and 9.89%, respectively (Jácome et al., 2010; Soares et al., 2005).

Although differences were found for flavonoids and tannins in detriment of seasonality, the comparison for the results found is made difficult due to methodological differences, using different proportions of dry mass of the plant for the analyzes. This, in part, explains the gross values between the periods, in addition to the environmental factors already described and recognized as secondary decomposing modulators in vegetables.

These compounds have antimutagenic, antineoplastic, antinoceptive, anti-inflammatory, anti-bacterial and gastroprotective effects and are found in different species. A limiting factor in the study of these compounds is the lack of nomenclature standardization,

thus hindering the data recovery in the literature. In the present review, the most common names used in the literature were used, besides providing different recurrent synonyms, as well as the general characteristics that may be accessed in the molecules registry in the PubChem.



**Figure 3.** Phytoconstituents molecular structure of different vegetative parts of *Davilla elliptica*. [1] (-)-epicatechin, [2] gallic acid, [3] kaempferol, [4] quercetin, [5] quercetin-3-glucoside, [6] quercetin-3-rhamnoside, [7] quercetin-3-O-β-D-galactopyranoside, [8] quercetin-3-O-β-D-glucopyranoside, [9] quercetin-3-O-β-D-glucopyranoside, [10] quercetin-3-O-β-D-glucopyranoside, [11] quercetin-3-O-β-D-glucopyranoside, [12] quercetin-3-O-β-D-glucopyranoside, [13] quercetin-3-O-β-D-glucopyranoside, [14] quercetin-3-O-β-D-glucopyranoside, [15] quercetin-3-O-β-D-glucopyranoside, [16] quercetin-3-O-β-D-glucopyranoside, [17] quercetin-3-O-β-D-glucopyranoside, [18] quercetin-3-O-β-D-glucopyranoside, [19] quercetin-3-O-β-D-glucopyranoside

quercetin-3-O- $\alpha$ -L-arabinopyranoside, [9] quercetin- 3-O- $\alpha$ -L-rhamnopyranoside, [10] myricetin, [11] myricetin-3-arabinoside, [12] myricetin-3-O- $\alpha$ -L-rhamnopyranoside, [13] myricetin-3-O- $\beta$ -D-galactopyranoside, [14] myricetin-3-O- $\beta$ -D-glucopyranoside, [15] myricetin-3-O-(2''-O-galloyl)- $\alpha$ -L- rhamnopyranoside, [16] myricetin- 3-O-(3''-O-galloyl)- $\alpha$ -L-rhamnopyranoside, [17] myricetin- 3-O-(2''-O-galloyl)- $\beta$ -D-galactopyranoside, [18] (6S,7E)-6,9-dihydroxy-4,7- megastigmadien-3-one, and [19] rutin.

## 9. Allelopathic activity

Besides the above-mentioned biological properties, phytotoxicity from extracts of *D. elliptica* was also observed to weed species. An inhibitory effect of 58% and 60% of the growth in coleoptiles of wheat were detected using 0.8 mg/mL of the methanolic extract derived from leaves and bark, *D. elliptica* respectively. In general, different extracts from leaves of *D. elliptica* (methanolic, acetonic or aqueous) resulted in significant inhibition of germination rate of weeds, with slight variations according to the plant species (Candido, 2016).

Significant variations were observed during the growth of wheat coleoptiles, under the activity of extract from different *D. elliptica* vegetative parts. The observed growth was proportional to the dose of the ethyl acetate fraction, extracted from the leaves of the species under study. The concentration adjustment from 0.2 mg/mL to 0.8 mg/mL, augmented the inhibition activity of 58% in wheat coleoptiles. However, the stem methanol extract (0.8 mg/mL), reduced 60% of the coleoptiles wheat growth (Candido, 2016).

The results obtained with the extracts application depend on the season when the extract was collected. In this context, the *D. elliptica* leaves extracts significantly decreased the lettuce seeds germination. The inhibition caused by the *D. elliptica* extracts was 75.9% (Gatti, 2008). For the gergelim germination, the *D. elliptica* extracts lead to a germination delay, when seeds were used from two different seasons (Gatti, 2008).

The *D. elliptica* leaves extract seems to be a potent phytotoxic that acts on the growth and development of *E. heterophylla* and *P. maximum* (known as “*amendoim-bravo*” and “*capim-colonião*”) (Candido, 2016). The different acetonic, methanolic and aqueous extracts of *D. elliptica* leaf inhibited the percentage of germination, mean time and average seed germination speed of *P. maximum*. On the other hand, this result was not observed in the germination of *E. heterophylla*. The leaves methanolic extracts were more sensitive when administered on the seeds of “*capim-colonião*,” especially in the radicular system where it

was observed a greater inhibition rate 70% in the concentration of 2 mg/mL, results compared to the commercial herbicide GOAL 59% (Candido, 2016).

The aqueous extract was responsible for 35% of the “capim-colonião” plantules that exhibited stunted roots. This result differed significantly from ethyl acetate (21%), acetone (15%) and methanolic (13%) acetate extracts (Candido, 2016).

Comparing the results of entropy for the leaves extracts collected in the dry and rainy seasons, it is possible to observe that the values obtained in the dry season were Higher, suggesting a higher greater synchrony on seed germination under the influence of these extracts (Candido, 2016).

For a better understanding by the reader, the inhibition related results 70%, 75.9% should be standardized.

## 10. Molluscicidal activity

Several human and domestic animals parasitic diseases have mollusks as intermediate hosts, such as snails of the genus *Biomphalaria*, the intermediate host of *Schistosoma mansoni*. Another example is fasciolosis that affects cattle, sheep and goat, significantly increasing the costs for the food industry. This disease has snails of the genus *Lymnaea* as the intermediate host in the parasite life cycle. In this scenario, with the aim to find natural products with molluscicidal activity, hydroalcoholic leaves extracts from two Brazilian Cerrado plant species, such as *D. elliptica* and *D. nitida*, were tested against snails of the genus *Lymnaea* (Gardioli et al., 2017). Although hydroalcoholic extracts of *D. nitida* and *D. elliptica* also presented molluscicidal activity against the *L. columella* species, extracts of *D. elliptica* were more prominent, triggering lethal molluscicides effects as soon as 6h after treatment using 100 mg/ml of hydroalcoholic extract concentration.

In contrast, *D. nitida* reached the same result only after 24 h of treatment. At the same concentration, a lethal dose of 50 (LD50) was determined within 24 h of exposure with extract of *D. elliptica*, resulting in 66% of mollusks deaths, whereas 33% were detected when extract of *D. nitida* was used. In addition, the hydroalcoholic extracts of *D. elliptica* showed an ovicide effect against *L. columella*, with an inhibitory effect of 60% after 15 days of treatment. This study seemed to reveal a potential effect of hydroalcoholic extracts of *D. elliptica*, being higher than its relative specie *D. nitida*, however the authors failed to perform statistical tests to assess the significance of the results.

Gardioli aimed to evaluate the molluscicide activity of the *D. elliptica* and *D. nitida* extracts human parasitic infection control through assessment of hydroalcoholic extract of

these species leaves on the motility and viability of mollusks in intervals of 2, 6, 12 and 24h, in final concentrations of 20, 25, 50 and 100 mg/mL (ppm). The results obtained by the authors point the *D. elliptica* extract as a potential agent in the control of snail's populations. Data point to an inhibitory concentration dose of 100 (IC) in a concentration of 100ppm in 6 hours, in contrast, the same dosage may be observed in the treatment with *D. nitida* extract; however, the latter extract IC was determined in 24 hours.

The 50 lethal doses of the *D. elliptica* species was determined on a 24 hours exposure period, resulting in 66% of mollusks deaths. These data counteract itself in the analysis performed with the *D. nitida* extract that registered a 33% death rate. Although the chemical composition analysis confirms the compounds to be similar between the two species. The *D. elliptica* presented better results; thus, in these perspectives, the authors suggest the synergism among diverse metabolites is responsible for such an effect, or even the majority concentration of determined metabolite. We hypothesize that this effect might be attributed to a specific active principle predominant in the extract.

Oviposition evaluation tests were used to test the inhibitory power of the studied extracts, confirming that the *D. elliptica* hydroalcoholic extract was capable of inhibiting 60% of the oviposition in a 15-days period, as compared to the negative control, evidencing the extract capacity to act as a molluscicide agent in spawns, leading to the mollusk death (*Lymnaea columella*). No results were observed in further dosages. The results were not contrasted; however, it was possible to verify the statistical significance of the exposed data (Gardioli et al., 2017).

## 11. Antibacterial activity

Analysis of the antimicrobial potential of leaves crude ethanolic extracts were evaluated, presenting efficient bactericidal and antimicrobial activities against gram-positive, gram-negative bacteria and *C. albicans*. Gram-positive strains are shown to be more sensitive to crude ethanolic extracts than gram-negative strains. It is suggested that these extracts action on these microorganisms occurs due to the synergism between tannins, flavonoids, and saponins (Soares et al., 2009).

The minimum inhibitory concentration (MIC), pointed in analysis performed with the crude ethanolic extract of the *D. elliptica* leaves, from a specific region in the Cerrado, is 0.37 mg/mL for the Gram-positive bacteria (MIC from 0.37 to 0.74 mg/mL for gram-negative bacteria and 0.37 mg/mL for *C. albicans* yeast). The *D. elliptica* crude ethanolic extract obtained from leaves in another Cerrado region presented MIC varying from < 0.02 mg/mL to

0.74 mg/mL for gram-positive bacteria, from <0.02 mg/mL to 11.9 mg/mL for gram-negative bacteria, and <0.02 mg/mL for yeast (*C. albicans*) (Soares et al., 2009).

Hypothetically, these variations occur at the expense of the chemical compounds concentrations present in the leaves, which may or may not be present in greater or lesser quantities, as the same species may undergo phenotypic variations between regions other than Cerrado. The results reported in this study (which were obtained by the agar dilution method) are not accompanied by details of how the plaques were read; thus, we may not affirm precisely the data inference, as they were not contrasted by statistical analysis.

In another antimicrobial assay using the *D. elliptica* extract in *Mycobacterium fortuitum*, the minimal inhibitory concentration (MIC) was 125 µg/mL, using dichloromethane as an extraction agent. However, the MIC values superior to 500 µg/mL were observed for the same plant species, *D. elliptica*, when polar extraction agents were used (i.e., ethanol and methanol). However, the study does not justify the absence of positive controls, and the obtained results were not statistically analyzed (Arantes et al., 2005).

Lopes et al., also reported *in vitro* antimicrobial effects of *D. elliptica* using chloroform extract of leaves tested against *Mycobacterium tuberculosis*. They found the plant extract was efficient as an antimycobacterial agent with a minimum inhibitory concentration of 62.5 µg/mL (Mascia Lopes et al., 2007). As mentioned by the authors, the extract was less effective as compared to the reference medication, the isoniazid (MIC = 0.03 µg / mL), because only the extract was tested.

Michelin et al. (2005) showed that methanolic extracts from *D. elliptica* leaves and bark presented antimicrobial activity against *Bacillus subtilis*, *B.cereus*, *Shigella* spp. and *Candida albicans*, but only the leaves methanolic extract was effective against *Enterococcus faecalis* and *Salmonella* spp. on the other hand, leaves and barks chloroform extracts applied on eight microorganisms species did not display antimicrobial activity. However, the leaves ethanolic extracts showed to be more efficient inhibiting the following six microorganisms' species, *B. subtilis*, *B. cereus*, *E. faecalis*, *Shigella* spp., *Salmonella* spp. and *C. albicans*, while the ethanolic bark extracts evidenced efficiency in four species *B. subtilis*, *B. cereus*, *Shigella* spp. and *C. albicans* (Michelin et al., 2005).

Although the results evidence satisfactory effects, it is not possible to quantitatively compare the mean significance of the different types of extracts tested, since statistical methods were not applied.

## 12. Gastroprotective activity

Pharmacological assays performed with ethanolic extracts (100 g/kg) from *D. elliptica* aerial parts inhibited 46% of ulcerogenic lesions caused by HCl/ethanol solution (Rinaldo et al., 2006). This can be justified by the presence of tannins, which are potent peroxide radical scavengers in addition to interacting with mucus proteins, improving their cytoprotective effect, forming a protein coating on the gastrointestinal mucosa (Okuda, 2005). This protective effect can still be attributed to the interaction of compounds such as polyphenols that act to strengthen the mucosal gastric barrier. These findings corroborate the popular use of *D. elliptica* as a gastroprotective compound (Kushima et al., 2009).

Pilote trials to define *D. elliptica* methanolic extract dosages on an experiment of colitis induced by trinitrobenzenesulfonic acid in male Wistar rats, demonstrated that the 500 mg/Kg dosage promotes the increase of colon injuries in 47%. These data are in agreement with Kushima et al., who verified a protective effect for methanolic extracts in gastric ulcer induced by HCl (0.3 M) and ethanol (60%) for the same dose (Kushima et al., 2009). Similar findings were observed for the treatment of gastric ulcers, where the *D. elliptica* ethanolic extract (500 mg/Kg) induced 65% more protection as compared to the negative control, a protective effect similar to the obtained with lansoprazole (69%), the standard drug used in the treatment of ulcers (Kushima, 2006).

In gastric lesions induced by stress, the *D. elliptica* treatment was gastroprotective in the dosages of 250 and 500 mg/Kg, protecting the gastric mucosa in the proportions of 83 and 75%, respectively. This same dosage demonstrated a significant wound healing activity in acetic acid-induced lesions, being capable of decreasing the size of the injury as compared to the control group (animals treated with saline), thus displaying more effective effects than the cimetidine (100 mg/Kg). It is argued that the extract elongates the mucosa glands localized in the regeneration area, findings not observed in the treatments with saline and cimetidine (Kushima, 2006).

In summary, the *D. elliptica* gastroprotective effect in different models of gastric lesions induction, confirm the popular knowledge regarding this species therapeutic properties. This extract has tannins fractions that present a gastroprotective impact, and its activity is associated with the nitric oxide and increased COX-1 expression. The ethanolic extract gastroprotective activity is related to the sulfhydryl groups and wound healing activity with reduction of the lesion area, but not altering the cellular proliferation (Kushima, 2006).

Aimed to comprehend the *D. elliptica* mechanisms in the gastric disorders, Vieira and cols evaluated the presence of elements such as phosphorus, selenium, chlorine, potassium,

calcium, titanium, chromium, magnesium, iron, nickel, copper, zinc, rubidium, and bromine (Vieira et al., 2018).

These chemical elements are responsible for exerting essential biological activities in the living organisms. The Ca, K and Zn, act in the diseases prevention and control, regenerating the damaged gastric mucosa, thus corroborating the popular use of *D. elliptica* to treat gastric disorders (Desideri et al., 2010; Koo, 1994; Watanabe et al., 1995).

The *D. elliptica* ethanolic extract S concentration is 3.019  $\mu\text{g/g}$ . This element, along with Mn, Fe and Cu play essential functions in the amino acids metabolism, where Cu is responsible for exerting functions related to growth, blood cells production, and iron transportation, whereas Mn and Fe are responsible for exerting essential immunomodulatory activities. The Cr chemical element act on the glucose, lipid and carbohydrate metabolism. Low Cr concentrations are associated with the development of cardiovascular diseases (Komarnisky et al., 2003; Marmiroli et al., 2008; Vieira et al., 2018).

The P element participates in metabolic processes and biological activities as part of organic molecules and component of enzymatic reactions, participating in the growth of the tissues and renew. Furthermore, the Cl element participates in the acid-base balance and osmotic stability among the cells (Desideri et al., 2010; Marmiroli et al., 2008; Nielsen, 2009).

### **13. Anti-inflammatory and antioxidant effect**

*D. elliptica* might be considered as a potential target to be used as a chemopreventive therapeutic agent, which can be perceived according to the data shown. The *D. elliptica* hexane fraction of the aerial parts had an inhibitory effect on NF- $\kappa$ B and COX-1 (Endringer et al., 2010). The aerial parts hydroalcoholic extract reduced the nociceptive response in the inflammatory phase via formalin test in mice, which suggests the involvement of the nitriding pathway. These results demonstrated that the extract presented an anti-inflammatory effect, with efficiency similar to diclofenac (Azevedo et al., 2007).

Concerning the isolated compounds, myricetin-3-O- $\beta$ -galactoside, isolated from the hydroalcoholic extract of the aerial plant parts, in concentrations of 0.26 and 0.78 mg/kg evidenced a reduction in paw edema induced by intraplantar injection of carrageenan in mice knockouts for the enzyme inducible nitric oxide (iNOS  $-/-$ ) to confirm the involvement of iNOS in the antinociceptive and anti-inflammatory mechanisms of action. This bioactive effect is attributed to the nitric oxide synthesis inhibition, mainly via iNOS. In the same study, the animals motor signs assessment did not display any changes (Azevedo et al., 2015).



The ethyl acetate and methanol fractions derived from the crude leaf extract showed a significant reduction in licking time in the formalin test late phase performed in animal models of paw edema induction (Jácome et al., 2010). Bioguided fractionation of the leaf methanol fraction resulted in the isolation of myricetin-3-O- $\beta$ -galactopyranoside, which produced significant inhibition in formalin-induced nociception at a concentration of 0.26 mg/kg. According to these findings, it is possible to infer that the antinociceptive effect of the *D. elliptica* species is attributed to the myricetin-3-O- $\beta$ -galactopyranoside component, which justifies its popular use for the attenuation of pain and inflammation (Campos et al., 2013).

A study performed by Kushima et al. (2009), showed that the methanolic extracts from the *D. elliptica* aerial parts orally administered in the following concentrations: 125, 250 and 500 mg/kg were not effective to reduce paw edema after carrageenan test. This effect was attributed to the tannins bioavailability in the extract. An evaluation of this extracts pharmacologic effect *in vivo* showed that the polymeric protoantocyanidines do not cross the intestinal wall and are not digested in the stomach (Kushima et al., 2009). However, the intraperitoneal administration in the concentrations of 7.81, 15.62 and 31.25 mg/kg caused a persistent reduction in the edema that was perceived 1 hour after application and resisted up to 4 hours. Differences were not observed among doses; however, the lowest doses presented late effect as compared to the others. Furthermore, investigating the anti-inflammatory effect of the tannin fraction, the 15.62 mg/Kg extract administration caused a 50% reduction in leukocyte recruitment induced by lipopolysaccharides (LPS) application in the post-capillary venules of the mice cremaster muscle (Nishijima et al., 2015).

The application of a tannins fraction (15.62 mg/kg) (via intraperitoneal administration) on an animal model evidenced 33% inhibition of paw edema; however, the leaves methanolic extract in the same dosage was capable of inhibiting 65% (Nishijima et al., 2015). As discussed by the authors, the extract is responsible for exerting a better anti-edematogenic activity as compared to the isolated tannins fraction. Therefore, the observed inhibition might be associated with the extract chemical constituent's synergism (Nishijima et al., 2015).

Another study performed to evaluate anti-edematogenic activity evidenced the tannins as efficient to inhibit leukocytes recruitment, consequently reducing edema. The decreased metallo-9-matrix proteinases (MMP-9) activation was also evidenced when mice were submitted to the *Bothrops jararaca* venom (Nishijima et al., 2015). Corroborating these findings, Nishijima et al. (2009), reported that the flavonoids responsible for the venom neutralization against the *B. jararaca* hemorrhagic activity are kaempferol, quercetin,

quercetin-3-O- $\beta$ -D-galactopyranoside, quercetin-3-O- $\alpha$ -L-arabinopyranoside and myricetin (Nishijima et al., 2009).

However, a decreased MMP-9 activity in the dermis compromised with poison + *D. elliptica* methanolic extract and a decreased pro-MMP-2 and MMP-9 activity in the compromised dermis in the group poison + *D. elliptica* tannins fraction (Nishijima, 2010).

The tannins seem to be responsible for decreasing 50% of the leucocytes "rolling" activity during the inflammatory process induced by LPS, where the *D. elliptica* extract chemical constituents must be the responsible agents with anti-inflammatory properties. (Nishijima, 2010).


Exploring the *D. elliptica* leaves biological effects on *Helicobacter pylori*-induced oxidative stress at the concentrations of 5, 50 and 100  $\mu\text{g/mL}$ , a dose-dependent improvement was observed. The concentration of 100  $\mu\text{g/mL}$  was efficient, presenting antioxidant activity above 80% (Bonacorsi et al., 2013), which was corroborated by an *in vitro* study that used *D. elliptica* leaves methanolic extract (250  $\mu\text{g/mL}$ ) on *H. pylori* (Kushima et al., 2009).

The investigation of other oxidative stress parameters, verified that the production of hydrogen peroxide ( $\text{H}_2\text{O}_2$ ) evaluated in immunological assays was not significantly increased in both leaves ethanol and methanolic extracts, however, both extracts showed a moderate release of nitric oxide (NO) by approximately 28  $\mu\text{M}$  (Carlos et al., 2005). Concerning the chloroform fraction, it was verified a dose-dependent production stimulation of  $\text{H}_2\text{O}_2$ , NO and tumor necrosis factor alpha (TNF- $\alpha$ ) in *in vitro* macrophage culture (Mascia Lopes et al., 2007). Once the MTT data was not reported in the study, it is not possible to make inferences regarding cell viability. Also, the reagents used were not fully described in the methods section.

It was also noticed that both methanolic and ethanolic extracts induced a marked TNF- $\alpha$  production, although the methanolic extract showed to be more efficient, producing almost five times more release of this cytokine as compared to the ethanolic extract. In summary, the results showed that methanolic and ethanolic extracts stimulated the production of NO and TNF- $\alpha$ , demonstrating immunostimulatory activity in mice, by modulating the activation of macrophages (Carlos et al., 2005).

Carli et al. (2009) found that leaves methanolic extract exerted immunosuppressive activity on LPS stimulated macrophages, presenting better results than the standard cis-Pt drug used in the treatment of cancer, which showed no NO formation inhibitory activity (Carli et al., 2009).

The main findings regarding the *D. elliptica* effects on gene expression modulation are summarized in Figure 4.



**Figure 4.** *Davilla elliptica* extract and compounds effects on inflammation, gastritis, colitis and oxidative stress.

Despite the different methodological settings (dosages, fractions, extracts), and experimental models used in the reported studies that aimed to evaluate the *D. elliptica* effects on inflammatory process and stress oxidative-associated conditions, it is possible to assess the protective and modulation role of inflammatory cytokines, as well as oxygen reactive species generating enzymes. However, studies aimed to investigate further the signaling pathways modulated by *D. elliptica* in inflammatory reactions are necessary. Additionally, the literature findings regarding the *D. elliptica* extract oral administration seem to be not effective to regulate inflammation as compared to the local application of the extract that was more

effective to inhibit inflammatory mediators recruitment, such as leucocytes and macrophages, and consequently, the cytokines response.

#### **14. Other biological activities**

Growing evidence has demonstrated promising molecules obtained from medicinal plants used in the treatment of neoplasms via diverse different action mechanisms. In this sense, flavonoids isolated from *D. elliptica* were tested on murine mammary tumor cells lineage LM2. In the MTT test for antitumoral activity evaluation, the following IC<sub>50</sub> values were obtained: from  $31.5 \pm 297$  to  $203.1 \pm 5.9$   $\mu\text{g/mL}$ . The compounds quercetin, quercetin-3-O-galactopyranoside, quercetin-3-O-arabinopyranoside, Myricetin-3-O- $\beta$ -galactopyranoside, myricetin, quercetin-3-O- $\alpha$ -L-rhamnopyranoside, and Myricetin-3-O- L-rhamnopyranoside displayed antitumoral effect, being more pronounced in the last two compounds (Carli et al., 2009).

The antimutagen effect is attributed to the *D. elliptica* chloroform extract. The micronucleus test in peripheral blood cells from male and female mice submitted to the acute treatment with cyclophosphamide (50 mg/Kg) was performed. The fraction demonstrated a significant reduction of cells with micronucleus, being 41.56%, 51.86% and 42.9% for the 111 mg/mL, 83.25 mg/mL and 55 mg/mL, respectively (Lira, 2007).

The quercetin, quercetin-3-O- $\alpha$ -L-rhamnopyranoside, myricetin, and myricetin-3-O- $\alpha$ -L-rhamnopyranoside flavonoids phytoestrogenic potential (E-Screen test) was investigated for the *D. elliptica* isolates by evaluating the MCF-7 and adenocarcinoma cells proliferation in different dosages, where no proliferative activity was detected. However, new studies need to be performed for more consistent conclusions. This may be justified by the absence of activity in the control with the steroid 17- $\beta$ -estradiol hormone, being necessary to review a more effective dosage for proliferation effects (Biso, 2008).

#### **15. Toxicity**

According to the data retrieval, only a few specific studies that evaluated the *D. elliptica* toxicity were published in the literature. However, different dosages and its actions were evidenced for the investigation of the extracts and fractions bioactive effects in in vitro and in vitro experiments, where alterations and toxic effects were observed.

Mutagenicity evaluation by the Ames test (Maron and Ames, 1983), performed by Biso and cols (Biso et al., 2010), observed different actions of the *D. elliptica* leaves fractions on *Salmonella typhimurium* strains with and without metabolization. In the trial performed without metabolization, the ethanolic and chloroform extracts showed evidence of

mutagenicity in TA97a lineage (12.53 mg/plate), while toxicity signs were observed in TA102 in the 8.35 and 12.53 mg/plate concentrations. In the presence of metabolism, the ethanolic, methanolic and chloroform fractions displayed genotoxic activity in TA98 (0.65-4.18 mg/plate), as verified by Lira in another study (Lira, 2007), while evidence of toxicity was observed for the aqueous fraction in TA79a and ethyl acetate TA98. For the T100 cells strain, the genotoxicity was confirmed (Biso, 2008). In another study that used the Ames model to evaluate the chloroform fraction antimutagen effect, a significant reduction in the TA95a lineage in the concentration of 1.04-8.35 mg/plate treated with the indirect mutagen 4-nitro-o-phenylenediamine, disagreeing with the toxicity evidence reported by Biso and cols in the same cells lineage and extracts concentration (Biso, 2008). However, according to Borstel et al. (1998), a few compounds that have antimutagenic activity may as well present themselves as mutagenic compounds, according to the experimental conditions (Von Borstel and Higgins, 1998).

To further investigate the *D. elliptica* extracts and fractions, Biso and contributors evaluated different isolated molecules in the pUC9.1 plasmid. The authors verified that the compounds quercetin, myricetin, quercetin-3-O- $\alpha$ -L-rhamnopyranoside, myricetin-3-O- $\alpha$ -L-rhamnopyranoside, and gallic acid did not induce breaks for any of the tested concentrations that were pre-defined according to the studies substances solubility. However, the addition of copper sulfate II resulted in the emergence of open circular DNA and linear DNA bands (Biso, 2008). On the other hand, Walcélío and contributors in a study with the chloroform fraction did not identify toxicity for quercetin-3-O- $\alpha$ -L-rhamnopyranoside, myricetin-3-O- $\alpha$ -L-aminopyranoside, and gallic acid in the dosages of 0.45 and 0.9 mg/mL, while the quercetin (0.9 mg/mL) presented plasmid DNA breaks, similarly to the tin chloride (200 $\mu$ L/mL). In this study, it was demonstrated an antimutagenic activity of the following compounds: galic acid (0.45 and 0.9 mg/mL) and myricetin (0.45 mg/mL) as compared to the tin chloride effects on plasmid DNA (Lira, 2007).

In the cytotoxicity test using MCF-7 cells lineages, it was verified cytotoxicity that after 24 hours of incubation with the quercetin (100  $\mu$ M) and myricetin (200  $\mu$ M). For the same dosages, it was verified an inhibition of the cell division for the quercetin-3-O- $\alpha$ -L-rhamnopyranoside and myricetin-3-O- $\alpha$ -L-rhamnopyranoside. Forty-eight hours incubation with quercetin (100 e 200  $\mu$ M), myricetin (100  $\mu$ M), and myricetin-3-O- $\alpha$ -L-rhamnopyranoside (200  $\mu$ M) resulted in reduced cell viability. Cells observed after 72 hours of incubation with the reported compounds, evidenced cytotoxicity for quercetin, quercetin-3-

O- $\alpha$ -L-rhamnopyranoside, myricetin and mirycetin-3-O- $\alpha$ -L-rhamnopyranoside in both dosages, except with quercetin-3-O- $\alpha$ -L-rhamnopyranoside at 100  $\mu$ M (Biso, 2008)

In the ex vivo evaluation of peritoneal macrophage modulation by methanolic and ethanolic extracts, both extracts exhibited the cytotoxicity index 50 (IC<sub>50</sub>) higher than the 300  $\mu$ g/mL dose; however, the dose ranges tested were not shown (Carlos et al., 2005). In vivo experiments with male Swiss mice treated with methanolic extract in single dosage (5000 mg) did not demonstrate behavioral alterations over 14 days, which presents absence of toxicity according to Loomis and Hayes (1996) (Kushima, 2006; Loomis and Hayes, 1996). Martins et al., on the other hand, pointed to alterations on spermatogenesis. Mice were treated with a flavonoid-rich fraction and *D. elliptica* hydroalcoholic extract for 42 days in the 100, 200 and 400 mg/Kg dosages by gavage. Both fractions demonstrated in the histological analysis a decrease of the total tubule length, decreased tubule and epithelial volume, where more pronounced effects were observed in the flavonoid-rich fractions (200 and 400 mg/Kg), but also in the hydroalcoholic extract in the 400 mg/Kg dosage. Moreover, the SOD activity (superoxide dismutase), the Leydig nuclei size and amount of connective tissue were increased in animals treated with a 400 mg/Kg dosage of the flavonoid-rich fraction. In the hydroalcoholic fraction test, increased GST (glutathione s-transferase) activity and decreased body weight and sperm motility was observed (Martins, 2018).

Although isolate effects were observed in the *D. elliptica* toxicity evaluations, a gap in the scientific literature is still present, since no dose response curves and different long-term vegetative parts were seen. Systemic effects should be explored to evaluate tissue damage in target organs (liver, kidneys, spleen, heart, and lung), as well as biochemical parameters to certify its safe use by the population.

## 16. Perspectives

The studies about the medicinal properties of *D. elliptica* have evidenced important bioactive activities such as anti-inflammatory, antimicrobial, gastroprotective, antioxidant and anti-tumoral. Also, molluscicide and allelopathic activities of hydroalcoholic extracts have been reported, although some studies will require additional validation using statistical parameters. Phytochemical studies have shown a diversity of secondary compounds such as triterpenes, steroids, catechins, flavonoids, saponins, phenolic acid derivatives, coumarins, condensed tannins, and tannins, as well as the presence of molecules such as gallic acid, myricetin, and derivatives isolated from this species. However, studies that evaluated the *D. elliptica* biological effects/mechanisms of action under different aspects and in different

vegetative parts, such as fruits, flowers, and seeds are scarce in the literature. These recent findings open perspectives for the investigation of new pharmacological properties of bioactive compounds present in *D. elliptica* and their use as a potential therapeutic agent.

### **Author's contributions**

JNS, VHDG, and SHSS conceived the study. JNS, VHDG, AFP, and VM wrote the manuscript. VHDG performed graphic designer present in figures. SHSS and DFL provided a critical revision of the paper. All authors read and have approved the final version of the paper.

### **Acknowledgements**

This work was partially supported by the Coordenadoria de Aperfeiçoamento do Pessoal de Nível Superior (CAPES- 25454) and Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) and Fundação de Amparo à Pesquisa do Estado de Minas Gerais (FAPEMIG).

### **Conflict of interest**

All authors do not have conflicts of interest.

## References

- Arantes, V.P., Sato, D.N., Vilegas, W., Santos, L.C., Leite, C.Q.F., 2005. Plantas do Cerrado brasileiro com atividade contra *Mycobacterium fortuitum*. Revista de Ciências Farmacêuticas Básica e Aplicada 26(3), 95-198.
- Azevedo, A.O., Campos, J.J., Galdino, G.S., Braga, F.C., Duarte, I.D., Perez, A.C., 2007. Antinociceptive effect from *Davilla elliptica* hydroalcoholic extract. Journal of ethnopharmacology 113(2), 354-356.
- Azevedo, A., Campos, J., de Souza, G., Veloso, C., Duarte, I., Braga, F., Perez, A., 2015. Antinociceptive and anti-inflammatory effects of myricetin 3-O- $\beta$ -galactoside isolated from *Davilla elliptica*: involvement of the nitregric system. Journal of Natural Medicine 69(4), 487-493.
- Aquino, F.d.G., Walter, B.M.T., Ribeiro, J.F., 2007. Dinâmica de populações de espécies lenhosas de Cerrado, Balsas, Maranhão. Embrapa Cerrados-Artigo em periódico indexado (ALICE).
- Akerele, O., 1993. Nature's medicinal bounty: don't throw it away. World Health Forum. 14(4):390-5.
- Biso, F.I., 2008. Avaliação da atividade mutagênica e fitoestrogênica das plantas *Davilla nitida* Vahl. e *Davilla elliptica* St. Hil (Dilleniaceae). Faculdade de Ciências Farmacêuticas da Universidade Estadual Paulista, Araraquara. Dissertation.
- Biso, F.I., Rodrigues, C.M., Rinaldo, D., Reis, M.B., Bernardi, C.C., de Mattos, J.C., Caldeira-de-Araujo, A., Vilegas, W., Colus, I.M., Varanda, E.A., 2010. Assessment of DNA damage induced by extracts, fractions and isolated compounds of *Davilla nitida* and *Davilla elliptica* (Dilleniaceae). Mutation research 702(1), 92-99.
- Bonacorsi, C., Fonseca, L.M.d., Raddi, M.S.G., Kitagawa, R.R., Vilegas, W., 2013. Comparison of Brazilian Plants Used to Treat Gastritis on the Oxidative Burst of *Helicobacter pylori*-Stimulated Neutrophil. Evidence-Based Complementary and Alternative Medicine (2013), 1-8.
- Bustamante, M., Martinelli, L., Silva, D., Camargo, P., Klink, C., Domingues, T., Santos, R., 2004.  $^{15}\text{N}$  natural abundance in woody plants and soils of central Brazilian savannas (Cerrado). Ecological Applications 14(sp4), 200-213.
- Barreira, S., Scolforo, J.R.S., Botelho, S.A., de Mello, J.M., 2002. Estudo da estrutura da regeneração natural e da vegetação adulta de um cerrado sensu stricto para fins de manejo florestal. The study of the natural regeneration structure and adult vegetation of cerrado sensu stricto. Scientia forestalis n. 61, p. 64-78.
- Campos, J.J., Azevedo de, O., Filho, J.D., Perez, A.C., Braga, F.C., 2013. Bioguided isolation of myricetin-3-O-beta-galactopyranoside with antinociceptive activity from the aerial part of *Davilla elliptica* St.-Hil. Journal of ethnopharmacology 150(1), 270-274.
- Carli, C.B., de Matos, D.C., Lopes, F.C., Maia, D.C., Dias, M.B., Sannomiya, M., Rodrigues, C.M., Andreo, M.A., Vilegas, W., Colombo, L.L., Carlos, I.Z., 2009. Isolated flavonoids against mammary tumour cells LM2. Zeitschrift fur Naturforschung. C, Journal of biosciences 64(1-2), 32-36.



- Carlos, I., Lopes, F., Benzatti, F., Carli, C., Marques, M.F., Jordão Junior, C.M., Rinaldo, D., Calvo, T.R., Santos, L.C., Vilegas, W., 2005. Action of *Davilla elliptica* St. Hill. (Malpighiaceae) methanolic and ethanolic extracts in the immune response. *Revista Brasileira de Farmacognosia* 15(1), 44-50.
- Candido, L.P., 2016. Busca de extratos e compostos ativos com potencial herbicida e inseticida nas espécies *Davilla elliptica* St. Hill e *Ocotea pulchella* Nees & Mart. . Universidade Federal de São Carlos, São Paulo. Thesis.
- Cragg, G. M., Newman, D. J., 2005. Plants as a source of anti-cancer agents. *Journal of Ethnopharmacology*. Aug 22;100(1-2):72-9.
- Dias, D. A., Urban, S. Roessner, U., 2012. A historical overview of natural products in drug Discovery. *Metabolites*. Apr 16;2(2):303-36
- Desideri, D., Assunta Meli, M., Roselli, C., 2010. Determination of essential and non-essential elements in some medicinal plants by polarised X ray fluorescence spectrometer (EDPXRF). *Microchemical Journal* 95(2), 174-180.
- Endringer, D.C., Valadares, Y.M., Campana, P.R., Campos, J.J., Guimaraes, K.G., Pezzuto, J.M., Braga, F.C., 2010. Evaluation of Brazilian plants on cancer chemoprevention targets in vitro. *Phytotherapy research* 24(6), 928-933.
- Fabricant, D. S., Farnsworth, N. R., 2001. The value of plants used in traditional medicine for drug discovery. *Environmental Health Perspectives*. Mar; 109(Suppl 1): 69–75.
- Felfili, J.M., 1995. Growth, recruitment and mortality in the Gama gallery forest in central Brazil over a six-year period (1985–1991). *Journal of tropical ecology* 11(1), 67-83.
- Felfili, J.M., Rezende, A.V., Júnior, M.C.D.S., Silva, M.A., 2000. Changes in the floristic composition of Cerrado sensu stricto in Brazil over a nine-year period. *Journal of Tropical Ecology* 16(4), 579-590.
- Fiedler, N.C., Rezende, A.V., Venturoili, F., 2004. Efeito de incêndios florestais na estrutura e composição florística de uma área de cerrado sensu stricto na fazenda Água Limpa-DF. *Revista Árvore* 28(1).
- Fraga, C.N.d., 2012. Filogenia e revisão taxonômica de *Davilla Vand.*(Dilleniaceae). , Instituto de Ciências Biológicas. . Universidade Federal de Minas Gerais, Belo Horizonte. Thesis.
- Gurni, A.A., Kubitzki, K., 1981. Flavonoid chemistry and systematics of the Dilleniaceae. *Biochemical Systematics and Ecology* 9(2-3), 109-114.
- Gurib-Fakim, A., 2006. Medicinal plants: traditions of yesterday and drugs of tomorrow. *Molecular aspects of medicine*. Feb;27(1):1-93. Epub 2005 Aug 18.
- Gardioli, T.S.G., Américo, B.A., Ignacchiti, M.D.C., Junior, O.d.S.P., 2017. Plantas do Cerrado Brasileiro como possíveis agentes moluscicidas. *Revista de Geografia-PPGEO-UFJF* 7(2).

- Gatti, A.B., 2008. Atividade Alelopática de Espécies do Cerrado. Universidade Federal de São Carlos. São Paulo. Thesis.
- Horn, J.W., 2009. Phylogenetics of Dilleniaceae using sequence data from four plastid loci (rbcL, infA, rps4, rpl16 intron). *International Journal of Plant Sciences* 170(6), 794-813.
- Iubatã P. Faria, Clarissa M. Knoechelmann, Marcel R. Cavallaro, Maria Alice de Medeiros, Moreno, M.I.C., Produção de frutos e sementes de *Davilla elliptica* St. Hil. (Dilleniaceae) em duas áreas de cerrado. 2003. p. 20. métodos de campo em ecologia (Projeto em grupo). Parque Estadual da Serra de Caldas Novas.
- Jácome, R.L.R.P., Oliveira, V.D.C., Oliveira, M.A.T., Mariano, M.C.F., Oliveira, A.B.d., 2010. Estudo farmacognóstico comparativo das folhas de *Davilla elliptica* A. St.-Hil. e *D. rugosa* Poir., Dilleniaceae. *Revista Brasileira de Farmacognosia* 20(3), 390-396.
- Komarnisky, L.A., Christopherson, R.J., Basu, T.K., 2003. Sulfur: its clinical and toxicologic aspects. *Nutrition* 19(1), 54-61.
- Koo, M.W., 1994. The effects of milk and calcium on ethanol-induced gastric mucosal damage. *Pharmacol Res* 29(3), 217-224.
- Kushima, H., 2006. Avaliação da atividade antiulcerogênica dos extratos e frações das folhas de *Davilla elliptica* St. Hil. e *Davilla nitida* (vahl) kubitzki (Dilleniaceae). . Universidade Estadual Paulista, Instituto de Biociências de Botucatu. São Paulo. Dissertation.
- Kushima, H., Nishijima, C.M., Rodrigues, C.M., Rinaldo, D., Sassa, M.F., Bauab, T.M., Stasi, L.C., Carlos, I.Z., Brito, A.R., Vilegas, W., Hiruma-Lima, C.A., 2009. *Davilla elliptica* and *Davilla nitida*: gastroprotective, anti-inflammatory immunomodulatory and anti-Helicobacter pylori action. *Journal of ethnopharmacology* 123(3), 430-438.
- Lenza, E., Klink, C.A., 2006. Comportamento fenológico de espécies lenhosas em um cerrado sentido restrito de Brasília, DF. *Revista Brasileira de Botânica* 29(4), 627-638.
- Lira, W.M., 2007. Avaliação do potencial mutagênico e antimutagênico de extratos e compostos vegetais obtidos a partir dos gêneros *Byrsonima* e *Davilla*. . Faculdade de Ciências Farmacêuticas de Araraquara., São Paulo. Thesis.
- Loomis, T., Hayes, A., 1996. *Essentials of Toxicology* 4th ed. Academic Press Limited, London.
- Mascia Lopes, F.C., Polesi Placeres, M.C., Jordao, C.M., Jr., Higuchi, C.T., Rinaldo, D., Vilegas, W., Fujimura Leite, C.Q., Carlos, I.Z., 2007. Immunological and microbiological activity of *Davilla elliptica* St. Hill. (Dilleniaceae) against *Mycobacterium tuberculosis*. *Memorias do Instituto Oswaldo Cruz* 102(6), 769-772.
- Michelin, D., M. Iha, S., Rinaldo, D., Sannomiya, M., C. Santos, L., Vilegas, W., Salgado, H., 2005. Antimicrobial activity of *Davilla elliptica* St. Hill (Dilleniaceae). *Revista Brasileira de Farmacognosia* 15(3), 209-211.
- Myers, N., Mittermeier, R.A., Mittermeier, C.G., da Fonseca, G.A.B., Kent, J., 2000. Biodiversity hotspots for conservation priorities. *Nature* 403(6772), 853.

- Medeiros, M.B., Miranda, H.S., 2005. Mortalidade pós-fogo em espécies lenhosas de campo sujo submetido a três queimadas prescritas anuais. Embrapa Recursos Genéticos e Biotecnologia-Artigo em periódico indexado (ALICE).
- Marmioli, N., Maestri, E., Prasad, M., 2008. Health implications of trace elements in the environment and the food chain. Trace Elements as Contaminants and Nutrients: Consequences in Ecosystems and Human Health 23, 53.
- Maron, D.M., Ames, B.N., 1983. Revised methods for the Salmonella mutagenicity test. Mutat Res 113(3-4), 173-215.
- Martins, A.L.P., 2018. Efeitos do extrato aquoso da flor de *dianthus caryophyllus* sobre os testículos de camundongos adultos. Universidade federal de viçosa. Dissertation.
- Mendes, F.R., Rodrigues, E., Negri, G., Tabach, R., Carlini, E.A., 2005. Cipó-caboclo (*Davilla rugosa* Poiret.): revisão, dados fitoquímicos e farmacológicos iniciais. J Bras Fitomed 3, 101-113.
- Nishijima, C.M., Rodrigues, C.M., Silva, M.A., Lopes-Ferreira, M., Vilegas, W., Hiruma-Lima, C.A., 2009. Anti-hemorrhagic activity of four Brazilian vegetable species against Bothrops jararaca venom. Molecules 14(3), 1072-1080.
- Nishijima, C.M., 2010. Caracterização do efeito anti-inflamatório e antihemorrágico dos extratos e frações enriquecidas de espécies vegetais do projeto temático BIOTA/FAPESP. . Universidade Estadual Paulista - Botucatu.
- Nishijima, C.M., Delella, F.K., Rodrigues, C.M., Rinaldo, D., Lopes-Ferreira, M.V., da Rocha, L.R., Vilegas, W., Felisbino, S.L., Hiruma-Lima, C.A., 2015. The Anti-Inflammatory Effects of the Methanolic Extract and Fractions from *Davilla elliptica* St. Hil. (Dilleniaceae) on Bothrops jararaca Envenomation. International journal of molecular sciences 16(6), 12454-12466.
- Nielsen, F.H., 2009. Major minerals-calcium, magnesium, and phosphorus. Nutrition and exercise concerns of middle age, 193–218.
- Okuda, T., 2005. Systematics and health effects of chemically distinct tannins in medicinal plants. Phytochemistry 66(17), 2012-2031.
- Pereira, I.M., 2014. Modelagem de distribuição e conservação de *Davilla Vand.* (Dilleniaceae salisb). Faculdade de Filosofia, Ciências e Letras de Ribeirão Preto/ USP. Thesis.
- Ribeiro, M.N., Sanchez, M., Pedroni, F., Peixoto, K., 2012. Fogo e dinâmica da comunidade lenhosa em cerrado sentido restrito, Barra do Garças, Mato Grosso. Acta Botanica Brasilica 26(1), 203-217.
- Rocha Filho, Léo Correia da Lomônaco, Cecília, 2006. Variações fenotípicas em subpopulações de *Davilla elliptica* A. St.-Hil.(Dilleniaceae) e *Byrsonima intermedia* A. Juss.(Malpighiaceae) em uma área de transição cerrado-vereda. Acta botanica brasilica.
- Rinaldo, D., Silva, M.A., Rodrigues, C.M., Calvo, T.R., Sannomiya, M., L.C.d.S., Vilegas, W., 2006. Preparative separation of flavonoids from the medicinal plant *Davilla*

- elliptica* St. Hill. by high-speed counter-current chromatography. *Quimica Nova* 29(5), 947-949.
- Rodrigues, V.E.G., Carvalho, D.A., 2001. Levantamento etnobotânico de plantas medicinais no domínio do cerrado na região do Alto Rio Grande - Minas Gerais. *Ciência e Agrotecnologia*, 25(1), 102-123.
- Rodrigues, C.M., Rinaldo, D., Sannomiya, M., dos Santos, L.C., Montoro, P., Piacente, S., Pizza, C., Vilegas, W., 2008. High-performance liquid chromatographic separation and identification of polyphenolic compounds from the infusion of *Davilla elliptica* St. Hill. *Phytochemical analysis* 19(1), 17-24.
- Santos, F.P.d., Ferreira, W.d.M., 2012. Estudo fenológico de *Davilla elliptica* St. Hill. e *Qualea grandiflora* Mart. em uma área de Cerrado sentido restrito em Porto Nacional, Tocantins. *Revista Interface (Porto Nacional)*, (05).
- Silvério, D.V., Lenza, E., 2010. Fenologia de espécies lenhosas em um cerrado típico no Parque Municipal do Bacaba, Nova Xavantina, Mato Grosso, Brasil. *Biota Neotropica* 10(3), 205-216.
- Soares, M., H. Rezende, M., D. Ferreira, H., D. L. Figueiredo, A., G. L. Bustamante, K., Bara, M., Paula, J., 2005. Pharmacognostic characterization of the leaves of *Davilla elliptica* St.-Hil.(Dilleniaceae). *Revista Brasileira de Farmacognosia* 15(4), 352-360.
- Soares, M.L., Bustamante, K.d.G.e.L., Figueiredo, A.D.L., Pimenta, F.C., 2009. Análise da atividade antimicrobiana das folhas de *Davilla elliptica* St.-Hil. (Dilleniaceae). *Revista de Ciências Farmaceuticas Básica e Aplicada*, 30(2), 183-186.
- Vieira, L.D., da Silva, K.T., Giarola, R.S., Inocente, G.F., Kushima, H., Hiruma Lima, C.A., Hormaza, J.M., 2018. Multielement analysis of plant extracts with potential use in the treatment of peptic ulcers by synchrotron radiation total reflection X-ray fluorescence. *PeerJ*.
- Veeresham, Ciddi. 2012. Natural products derived from plants as a source of drugs. *Journal of Advanced Pharmaceutical Technology & Research*. 3(4): 200–201.
- Von Borstel, R.C., Higgins, J.A., 1998. Janus carcinogens and mutagens. *Mutat Res* 402(1-2), 321-329.
- Watanabe, T., Arakawa, T., Fukuda, T., Higuchi, K., Kobayashi, K., 1995. Zinc deficiency delays gastric ulcer healing in rats.
- Woods, P., 1989. Effects of logging, drought, and fire on structure and composition of tropical forests in Sabah, Malaysia. *Biotropica*, 290-298.

## 5.2 PRODUTO 2

### **Effects of oral treatment with leaf and extract of *Davilla elliptica* on diet-induced obese mice**

Jaciara Neves Sousa<sup>1</sup>, Victor Hugo Dantas Guimarães<sup>1</sup>, Valéria Mafra Cota<sup>2</sup>, Sérgio Henrique Sousa Santos<sup>1,3\*</sup>

<sup>1</sup>Laboratory of Health Science, Postgraduate Program in Health Science, Universidade Estadual de Montes Claros (Unimontes), Minas Gerais, Brazil.

<sup>2</sup>Federal Institute of Education, Science and Technology of the North of Minas Gerais (IFNMG), Januária, Minas Gerais, Brazil

<sup>3</sup>Institute of Agricultural Sciences (ICA), Food Engineering, Universidade Federal de Minas Gerais (UFMG), Belo Horizonte, Minas Gerais, Brazil.

\* Correspondence to Sérgio Henrique Sousa Santos, Institute of Agricultural Sciences. Food Engineering College, Universidade Federal de Minas Gerais (UFMG); Avenida Universitária, 1.000 – Universitário, 39.404-547, Montes Claros, MG, Brazil. E-mail: sergiosousas@hotmail.com.

#### **ABSTRACT**

*Ethnopharmacological relevance:* *Davilla elliptica* A. St.-Hil, popularly known as “*lixerinha*”, is a shrub belonging to the Dilleniaceae family that occurs naturally in the Brazilian Savannah (Cerrado). In popular medicine, *D. elliptica* has been used to treat gastritis, ulcers and diarrhea. Research studies have proven evidences of its gastroprotective effect, as well as, its benefits as anti-nociceptive, anti-inflammatory, antioxidant. However there are no studies that have tested the potential effects of *D. elliptica* on metabolic parameters and obesity.


*Aims:* This study aimed to evaluate the effect of *Davilla elliptica* leaf extract in the metabolic parameters of in diet-induced obese mice, as well as to carry out the phytochemical characterization of the species.

**Materials and methods:** Leaves of *D. elliptica* were used to obtain an hydroalcoholic extract and phytochemical assays were performed. Animal experimentation was carried out using male Swiss mice divided into eight groups: ST (Standard), ST plus EA (fraction ethyl acetate), ST plus HE (hydroalcoholic extract), ST plus PL (leaf powder), HFD (obese control), HFD plus EA (fraction ethyl acetate), HFD plus HE (hydroalcoholic extract), HFD plus PL (leaf powder) and treated for four weeks. Insulin sensitivity and glucose tolerance tests were performed one week prior to sacrifice. Plasma analyzes of triglyceride, total cholesterol and glycemia levels were measured by ELISA kit.

**Results:** A significant reduction of adiposity and body weight between obese groups was verified. Statistical differences in the biochemical analyzes, triglycerides and total cholesterol were observed in the animals of the standard group treated with fraction of *D. elliptica*, and surprisingly, the adiposity in this group was increased.

**Conclusions:** Oral treatment with *D. elliptica* reduce adiposity and body weight, improving plasma levels of triglycerides and total cholesterol. However, further analyzes are needed to investigate which molecular mechanisms are involved with the modulation of metabolism upon treatment of mice with this extract.

### Graph abstract:



**Key words:** Sambaibinha; Adiposity; Flavonoids; Brazilian Savanna; Diet- induced.

**Abbreviators:**

WHO (World Health Organization); HFD (High- fat diet); ST (Standart); EA (Ethyl acetate); HE (Hydroalcoholic extract) PL (leaf powder); UCP1 (Uncoupling protein 1); SIRT1 (Sirtuin); PGC-1 $\alpha$  (Peroxisome proliferator- activated receptor –gamma coactivator 1 alpha); BAT (brown adipose tissue).

## 1. INTRODUCTION

Obesity is defined as a metabolic disorder characterized by abnormal body fat accumulation and imbalance between consumption and energy expenditure (Despres and Lemieux, 2006; Hill et al., 2000; Lee et al., 2017). According to data from the World Health Organization (WHO), obesity has almost tripled since 1975, and by 2016, more than 1.9 billion adults were overweight, from which over 650 million were obese. The majority of the world's population lives in countries where overweight and obesity is the leading cause of death (World Health Organization and WHO, 2018).

Pharmacotherapy may alternatively be used as an adjunct in the treatment of obesity and lifestyle modifications. Medications used in the treatment of obesity have side effects; in this sense, natural compounds and medicinal plants have been suggested as a therapeutic method (Cordido et al., 2014). Studies have shown that endemic species of the Brazilian Savanna seem to exert positive effects on obesity by improving oral glucose tolerance, insulin sensitivity and inflammatory responses in adipose tissue and liver (Oliveira et al., 2014).

*Davilla elliptica* (Dilleniaceae) A. St.-Hil, also popularly known as “lixerinha”, “sambaibinha”, “muricizinho”, “cipó-caboclo” e “cipó-de-carijó”(Soares et al., 2005; Rodrigues et al., 2002; Rodrigues et al., 2001) is a native species of the Brazilian Savanna, occurring in the Pandeiros river basin, and presenting shrub habits and branched sub-bushes (Jácome et al., 2010). This plant presents in its chemical composition a wide diversity of secondary metabolism substances, such as flavonoids, saponins, steroids, tannins, coumarins and triterpenoids. These bioactive compounds have anti-inflammatory, antioxidant, antitumoral, anti-nociceptive, anti-microbial, anti-mutagenic and gastroprotective activities (Carlos et al., 2002).

The molecular mechanisms through which *D. elliptica* act are still unknown due to lack of studies addressing. Therefore, the present study aims to evaluate the therapeutic potential of *D. elliptica* over metabolic parameters of from diet- induced obese mice.

## 2. MATERIALS AND METHODS

### 2.1 Plant material

For the achievement of the study, *Davilla elliptica* St.-Hil leaves, collected between July and August 2018 in the municipality of Bonito de Minas - Minas Gerais, Brazil (15°13'31.37 "S and 44°55'1.52" W) (Figure 1), were used. Herbarium specimens of *D. elliptica* may be found in the Herbarium of the State University of Montes Claros, under registry No. 332.



Figure 1. Location map of the study area. Source: Google Earth.

### 2.2 Extract

#### 2.2.1 Preparation of Plant Material

Leaves of *D. elliptica* were harvested, washed thoroughly in current water and dried in a drying stove with air circulation (New Ethics) under heating and air circulation at 38°C ( $\pm 2$ ). Subsequently, the plant material was pulverized in a Willey-type mill, packed in paper containers and kept under refrigeration (5°C) for preparation of the extracts (Rotta et al., 2008).

#### 2.2.2 Maceration

The pulverized samples of *D. elliptica* leaves were conditioned in the proportion of 10 mL of absolute ethanol for each gram of plant powder. The mixture was stored for one week,



and then it was filtered and placed in an drying stove at  $35 \pm 2$  °C. After drying the solvent, the samples were stored in the refrigerator at 10 C.

### 2.2.3 Extract partitioning

For the fractionation of the flavonoid extract, the samples obtained in the previous procedure were resuspended in a mixture of ethanol: water (7:3), in the ratio of 3 g of extract to 250 mL of 70% ethanol. At the first wash of the mixture, 200 mL of hexane PA were added three times. A volume of 200 mL ethyl acetate was added three times to the first wash residue. Partitions containing the compounds of interest were brought to the stove under air circulation at 38 °C until the solvents dried (Andreo and Jorge, 2006).

### 2.2 Qualitative chemical screening

Using the dry leaves, qualitative tests were performed to detect the content of tannins, saponins, flavonoids, alkaloids and phenolic compounds: 10% neutral lead acetate and 2% iron chloride for tannins, 2% iron chloride and Shinoda reactions for flavonoids, Mayer's Reagents, Bouchadart, Bertrand and Dragendorf for alkaloids, persistent foam test for saponins. The positive result is interpreted by the formation of greenish color (Marcela et al., 2015).

### 2.4 Animals

The experiment was conducted with forty *SWISS* male mice (six weeks old), from the State University of Montes Claros animal. The animals were housed in cages under the 12:12h light-dark cycle (lights from 7 a.m. to 7 p.m.) at  $25.0 \pm 2.0$ °C. After a 7-day adjustment period, the mice were randomly divided into eight groups ( $n = 5$  per treatment), followed by induction of obesity for 3 months. After this period, the animals were fed the following diets for 4 weeks: Standard Diet (ST); ST plus EA (fraction of ethyl acetate); ST plus HE (hydroalcoholic extract) ; ST plus PL (leaf powder); High fat diet (HFD); HFD plus EA (fraction of ethyl acetate); HFD plus HE (hydroalcoholic extract) ; HFD plus PL (leaf powder)(0.26 mg/Kg/body weight) (Azevedo et al., 2015, Campos et al., 2013). Food and water were offered *ad libitum*. This study was approved by the Ethics Committee on Animal Experimentation and Welfare of the State University of Montes Claros, Brazil (process No. 164/2018).

## 2.5 Diets

The standard diet (Purina - Labina ®) used for regular maintenance of mice was composed of 50.3% carbohydrate, 41.9% protein and 7.8% fat, representing a total of 2.18 kcal per 1g of diet. The high-fat diet was composed of 36.59% carbohydrate, 12.88% protein and 50.53% fat, presenting a total of 5.1 kcal per 1 g of diet. All components of the high fat-diet were purchased from Rhostrer LTDA (São Paulo, Brazil).

## 2.6 Tests of glucose tolerance and insulin sensitivity

For the glucose tolerance test, D-glucose (2 mg/g body weight) was injected intraperitoneally into mice fasted over a period of 12 hours. Glucose levels of the tail blood samples were monitored at 0, 15, 30, 60 and 120 min. An insulin sensitivity test was performed on mice in the fed state after intraperitoneal injection of insulin (0.75 units/kg body weight). Tail blood samples were obtained at 0, 15, 30 and 60 min after injection. Glucose levels were assessed on an Accu-Check glycometer (Roche Diagnostics®, Indianapolis, USA).

## 2.7 Measures of body weight, food intake, tissue collection and plasma parameters.

Food intake was measured twice a week throughout the treatment to ensure food efficiency (food intake/body weight). At the end of the experiment, the animals were fasted overnight (12h) and euthanized by decapitation. Samples were collected, weighed, stored immediately in liquid nitrogen and stored at -80°C for further analysis.

## 2.8 Blood measurement determination

Serum was obtained after centrifugation (3200 rpm for 10 min). Total serum cholesterol, triglycerides and glucose were evaluated using enzyme kits (Wiener® Argentina).

## 2.9 Statistical analyzes

All data were analyzed by Graph Pad Prism software (version 5.0®, San Diego, USA) and subjected to specific tests with a statistical confidence of 95% ( $p < 0.05$ ). Data are expressed as the mean  $\pm$  error of the mean (SEM). The statistical significance of differences in mean values between the groups of mice was assessed by one-way ANOVA or two-way ANOVA and Tukey's post-test.

### 3. RESULTS

#### 3.1 Phytochemical screening, flavonoid quantification from *Davilla elliptica* leaves.

The qualitative evaluation of secondary metabolites: tannins, alkaloids, flavonoids, saponins and phenolic compounds of *D. elliptica* leaves are described in Table 1. The results were positive for saponin heterosides and hydrolyzable tannins, as well as the alkaloids and flavonoids present in the leaves in hydroalcoholic extract.

**Table 1.** Phytochemical screening of extract of *Davilla elliptica*

Class	Test	Leaf
Tannins	Ferric chloride	+++
	Copper acetate	+++
	Neutral lead acetate	++
Flavonoids	Iron chloride	++
	Sodium hydroxide	+
	Mayer reagente	++
Alkaloids	Bouchadart reagente	+
	Bertrand reagente	+++
	Dragendorff reagente	++
Phenolic compounds	Iron chloride	+
	Sodium hydroxide	++

(-) Negative, (+) Weak positive, (++) Moderate positive, (+++) Strong positive.

Saponin		
H <sub>2</sub> O	EX	
5	-	-
4	1	+
3	2	+
2	3	+
1	4	++
-	5	++

(-) Negative, (+) Weak positive, (++) Moderate positive, (+++) Strong positive.

#### 3.2 Treatment with *D. elliptica* improved metabolic parameters in HFD-fed mice.

Adiposity was significantly decreased in the HFD plus EA group mean  $\pm$  standard error ( $0.0470 \pm 0.0078$ ) compared to the obese control ( $p < 0.01$ ); differences between treated

groups were also observed for HFD plus EA ( $0.0470 \pm 0.0078$ ) vs. HFD plus HE ( $0.0767 \pm 0.0017$ )  $p < 0.01$ , and HFD plus EA ( $0.0470 \pm 0.0078$ ) vs. HFD plus PL ( $0.0806 \pm 0.0074$ )  $p < 0.05$ . As observed the body weight gain was lower in the groups HFD plus EA ( $48.10 \pm 0.3390$ ) and HFD plus PL ( $52.68 \pm 0.4536$ ), when compared to the obese control group HFD ( $57.01 \pm 0.7890$ ),  $p < 0.01$ . Differences between treatments could also be observed for HFD plus EA ( $48.10 \pm 0.3390$ ) vs. HFD plus HE ( $55.79 \pm 1.055$ ), HFD plus EA ( $48.10 \pm 0.3390$ ) vs. HFD plus PL ( $52.68 \pm 0.4536$ ), and HFD plus HE ( $55.79 \pm 1.055$ ) vs. HFD plus PL ( $52.68 \pm 0.4536$ ) (Figure 1. A-B)

Interestingly, adiposity was significantly increased in ST plus EA ( $0.0372 \pm 0.0049$ ) when compared to the ST control group ( $0.0196 \pm 0.0036$ ) ( $p < 0.05$ ). Differences in ST plus EA ( $0.1857 \pm 0.0192$ ) vs. ST plus HE ( $0.1183 \pm 0.0238$ ) were observed, the ST plus PL group ( $0.0174 \pm 0.0032$ ) had a reduced adiposity when compared to the ST plus EA group ( $0.1857 \pm 0.0192$ ). There were no significant differences in body weight gain in treated ST groups (Figure 1 C-D).




Figure 1. Effects of *D. elliptica* about adiposity and body weight of animals in treatment with high- fat diet and standard diet. (A, C) Sum of all white adipose tissues: epididimal, mesenteric and retroperitoneal. (B, D) Mean weight of the animals during the treatment period 30 days. Values shown are mean  $\pm$  standard error (SEM) (n = 05). Significant differences,

using one-way ANOVA and Tukey's post-test, are indicated by asterisks \* ( $p < 0.05$ ); \*\* ( $p < 0.01$ ); \*\*\* ( $p < 0.001$ ). ST: Standard (Control), HFD: High-fat diet (Control), EA: Fraction ethyl acetate, HE: hydroalcoholic extract, and PL: leaf powder.

### 3.3 Biochemical parameters

Significant differences were observed in the total cholesterol levels of the animals treated with standard ST diet ( $285.3 \pm 32.80$ ) vs. ST plus EA ( $155.2 \pm 5.886$ )  $p < 0.01$ , ST ( $285.3 \pm 32.80$ ) vs. ST plus HE ( $128.8 \pm 11.67$ )  $p < 0.001$ , and ST ( $285.3 \pm 32.80$ ) vs. ST plus PL ( $145.7 \pm 10.91$ )  $p < 0.001$ . Levels of triglycerides were significantly decreased between ST groups ( $442.7 \pm 54.91$ ) vs. ST plus EA ( $237.6 \pm 47.83$ )  $p < 0.05$ , and ST ( $442.7 \pm 54.91$ ) vs. ST plus PL ( $162.7 \pm 22.53$ )  $p < 0.0$ . (Figure 2 D-F). No statistical differences were found in plasma glucose, triglyceride and total cholesterol levels between treated obese groups (Figure 2A-C).




Figure 2. Effects of oral administration of hydroalcoholic extract, ethyl acetate fraction and leaf on total cholesterol, triglycerides and high density lipoprotein levels in mice fed standard or high-fat diet. Values shown are mean  $\pm$  SEM ( $n = 05$ ). Significant differences, using one-way ANOVA and Tukey's post-test, are indicated by asterisks \* ( $p < 0.05$ ); \*\* ( $p < 0.01$ ); \*\*\*

( $p < 0.001$ ). ST: Standard (Control), HFD: High-fat diet (Control), EA: Fraction ethyl acetate, HE: hydroalcoholic extract, and PL: leaf powder.

### 3.4 Insulin sensitivity and glucose tolerance tests

In mice fed a high-fat diet, the insulin sensitivity test demonstrated a decrease in blood glucose levels of group obese treated with fraction of the ethyl acetate compared to HFD ( $554.9 \pm 89.39$ ) vs HFD plus EA ( $316.3 \pm 17.68$ ) ( $p < 0.05$ ) (Figure 3 A-B). This result was accompanied by the glucose tolerance test that demonstrated a reduction in glucose levels in the HFD plus EA group when compared to the control group obese HFD ( $1507 \pm 241.9$ ), HFD plus EA ( $897.0 \pm 48.35$ ) ( $p < 0.05$ ) (Figure 3C-D). These results indicate that the ethyl acetate fraction prevented the increase of glycemia even when consuming a high-fat diet. For the groups treated with standard diet the results of the test of glucose tolerance and insulin sensitivity did not present statistical difference (Figure 4 A-D).




Figure 3. Effects of oral administration of hydroalcoholic extract, ethyl acetate fraction and leaf powder of *D. elliptica* on insulin sensitivity, glucose tolerance levels in mice fed a high-fat diet. (A, B) Intrapерitoneal Insulin Sensitivity Test (IPIST) and area under the curve

(mg/dL) (C, D) Intraperitoneal glucose tolerance test (IPGTT) and IPGTT glucose area under the curve. Significant differences, using two-way ANOVA and Tukey's post-test, are indicated by asterisks \* ( $p < 0.05$ ); \*\* ( $p < 0.01$ ); \*\*\* ( $p < 0.001$ ). IPIST: Intraperitoneal Insulin Sensitivity Test, IPGTT: Intraperitoneal Glucose Tolerance test, HFD: High-fat diet (Control), EA: fraction ethyl acetate, HE: hydroalcoholic extract and PL: leaf powder.




Figure 4. Effects of oral administration of hydroalcoholic extract, ethyl acetate fraction and leaf powder of *D. elliptica* on insulin sensitivity, glucose tolerance and fasting glucose levels in mice fed a standard diet. (A, B) Intraperitoneal Insulin Sensitivity Test (IPIST) and IPIST insulin area under the curve (mg/dL) (C, D) Intraperitoneal glucose tolerance test (IPGTT) and IPGTT glucose area under the curve. Significant differences, using two-way ANOVA and Tukey's post-test, are indicated by asterisks \* ( $p < 0.05$ ); \*\* ( $p < 0.01$ ); \*\*\* ( $p < 0.001$ ). IPIST: Intraperitoneal Insulin Sensitivity Test, IPGTT: Intraperitoneal Glucose Tolerance test, ST: Standard, EA: fraction ethyl acetate, HE: hydroalcoholic extract and PL: leaf powder.

## 4. DISCUSSION

Our results indicate that the leaves of *D. elliptica* acts on the treatment of obesity, reducing adiposity and body weight, increasing insulin sensitivity of obese mice induced by diet, also improving plasma levels of triglycerides and total cholesterol of mice fed with a diet standard.

### 4.1 Compounds present in the leaves of *D. elliptica*

The compound classes of flavonoids, tannins and saponins were also described previously, in a phytochemical study with leaves and bark of *D. elliptica* (Michelin et al., 2005). The same results were elucidated by Guaraldo et al. (2001), with studies made from the stems of *D. rugosa*. Therefore, it is possible to infer the presence of these compounds in the different structures of the plants, and also that the species of the genus have similar compounds, differing only in tannin and flavonoid content (Guaraldo et al., 2001; Jácome et al. 2010). In a previous study with the leaves of *D. elliptica*, the results were positive for flavonoids, triterpenoids, steroids, gallic acid and catechins (Carlos et al., 2000; Soares et al., 2005).

Flavonoids, the products of secondary plant metabolism, exhibit antioxidant activity as well as effects on cardiovascular diseases. In a context of inflammation, some of the mechanisms of action of flavonoids are responsible for modulating the gene expression of cytokines (Panche et al. 2016). Our study evaluates the effect of the ethyl acetate fraction, rich in flavonoids on obesity.

### 4.2 Metabolic parameters

As we observed the increase in body composition and adiposity between ST groups vs. ST plus EA, we hypothesized that the effects of the polyphenols present in the ethyl acetate fraction are directly dependent on the amount and uptake of the polyphenols from the diet, through the gastrointestinal tract.

We suggest that the effects of *D. elliptica* observed in the treatment of obesity are due to the interaction of compounds present in larger quantities in the leaves of the species under study and that possibly the synergism between these compounds, quercetin, myricetin and its ramifications, are responsible for a mechanism not yet described in the literature.

Studies with myricetin have shown a decrease in body weight gain in obese animals, but differences in daily intake have not been observed (Chang et al., 2012), resembling the observations made in our study. In contrast, animals treated with quercetin showed no



difference in body weight gain or body composition. These findings corroborate in part with our study when we observed body weight effects in the ST group (Kuipers et al., 2018).

It is assumed that bioactive compounds are present in crude extracts at lower concentrations, acting through a combination of additive and synergistic effects (Kim et al., 2017; Seeram et al., 2004). Similar results were also reported by Kim et al. (2017) in an *in vivo* study using methanolic extract of *Limonium tetragonum* shoot, in which the presence of myricetin-3-O- $\beta$ -D-galactopyranoside compound reduced significantly obese mouse adiposity. On the other hand, differences between food consumption were not reported (Kim et al., 2017).

Supposedly, adiposity is intrinsically related to the activation of brown adipose tissue (BAT). According to studies by Hu et al. (2018), myricetin, a dietary flavonoid present in leaves of *D. elliptica*, is responsible for activating BAT by increasing the expression of thermogenic proteins such as UCP1, SIRT1 and PGC1 $\alpha$ , which appear to be responsible for modulating mitochondrial biogenesis (Hu et al., 2018) and may be a mechanism through which *D. elliptica* acts.

#### 4.3 Plasma analyzes

We hypothesize that the effects observed in the reduction of triglyceride levels and total cholesterol in ST group animals are due to the interaction between the compounds myricetin and quercetin. These compounds are present in large quantities in *D. elliptica* leaves, as demonstrated in studies (Biso et al., 2010; Rodrigues et al., 2008), being responsible for altering the process of fatty acid uptake by adipocytes, a mechanism not yet elucidated.

Attributed to the effect of quercetin, studies have shown a reduction in plasma levels of triglycerides and fatty acids, associated with an increased flow of fatty acids, derived from triglycerides in relation to subcutaneous adipose tissue, which during this process undergoes a differentiation through the “browning” process (Kuipers et al., 2018). The mechanism behind these effects and the ability of quercetin to induce browning of adipocytes still need to be elucidated.

*In vitro* studies demonstrated that *L. tetragonum* extract inhibited fat accumulation during differentiation of 3T3-L1 pre-adipocytes in a dose-dependent manner, at a concentration of 6.25-50  $\mu$ g/mL. This finding demonstrates that both the compound quercetin and myricetin may act on the browning process, reducing plasma levels of triglycerides and total cholesterol (Kim et al., 2017).

Quercetin seems to be a potent modulator of plasma triglyceride levels, and studies in humans and animal models suggest that quercetin is a possible new agent on metabolic parameters (Hoek-van den Hil et al., 2013; Kuipers et al. Sahebkar, 2017).

#### 4.4 Glucose intolerance and insulin sensitivity

In previous studies, the use of quercetin, a compound isolated from *Phyllanthus emblica* fruit methanolic extracts, promoted a highly effective antihyperglycemic response in streptomycin-induced diabetic rats. Elevated plasma glucose levels decreased markedly after oral administration of the compound (Srinivasan et al., 2018). We did not observe the effects of glucose on obese mice induced by diet and treated with extract, fraction and leaf of *D. elliptica* although quercetin is one of the constituents of this extract. Possibly, the presence of other bioactive compounds in small concentrations may interact with the molecules already described and promote these results.

Other findings confirm the isolated action of compounds on glucose. Plasma glucose levels were also significantly decreased in myricetin-treated *db/db* mice (Hu et al., 2018).

The compounds myricetin and quercetin present in the aqueous extract of *Chrysobalanus icaco* leaves at the concentration of 0.35 mg/mL significantly reduced the blood glucose levels of animals treated with an ST diet when compared to the HFD groups (White et al., 2016). Hence, the aqueous extract of *Chrysobalanus icaco* significantly normalized glucose tolerance.

Shao et al. (2013) demonstrated in their studies that the presence of flavonoids such as quercetin modulates glycemic homeostasis against inflammation in animal models, inducing glucose intolerance and attenuating insulin sensitivity (Shao et al., 2013).

A Chinese medicinal formula prepared with *Gynostemma pentaphyllum* and consumed as tea reduced serum glucose, lowering glucose intolerance in diet-induced obese mice, so that tea screening confirmed the presence of quercetin and its glycosides (Guruvaiah et al., 2018).

Theoretically, some flavonoids may act by suppressing the intestinal lipid diatal adsorption, inhibiting pancreatic lipase (Seyedan et al., 2015), or these compounds may act on the browning process of white adipose tissue, which is considered a potential therapeutic target for treatment of obesity and metabolic diseases.

Supposedly, the synergistic effects of *D. elliptica* treatment for anti-obesity treatment may act through more than one mechanism or signaling pathway. Also, a hypothesis worth

considering is that the treatment with this plant may lead to increased thermogenesis through elevated UCP1 gene expression (Fu et al., 2016).

## **5. CONCLUSION**

In conclusion, the findings of the present study indicate the *Davilla elliptica* may be a therapeutic alternative in treatment of obesity decreasing adiposity by improving plasma levels of total cholesterol, triglycerides and increasing insulin sensitivity. However, new studies need to be performed to elucidate which pathways *D. elliptica* acts on the obesity process.

### **Author's contributions**

JNS and SHSS conceived the study. JNS, wrote the manuscript. VHDG performed graphic designer present in figures. SHSS and VMC provided a critical revision of the paper. All authors read and have approved the final version of the paper.

### **Acknowledgements**

This work was partially supported by the Coordenadoria de Aperfeiçoamento do Pessoal de Nível Superior (CAPES- 25454) and Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq) and Fundação de Amparo à Pesquisa do Estado de Minas Gerais (FAPEMIG).

### **Conflict of interest**

All authors do not have conflicts of interest.

## References

- Azevedo A. O., Campos, J.J., de Souza, G.G., Veloso Cde, C., Duarte, I.D., Braga, F.C., Perez Ade, C., 2015. Antinociceptive and anti-inflammatory effects of myricetin 3-O-beta-galactoside isolated from *Davilla elliptica*: involvement of the nitregric system. *Journal of natural medicines* 69(4), 487-493.
- Andreo, D., Jorge, N., 2006. Antioxidantes naturais: técnicas de extração. *B. do CEPPA* 24(2), 319-336.
- Biso, F.I., Rodrigues, C.M., Rinaldo, D., Reis, M.B., Bernardi, C.C., de Mattos, J.C., Caldeira-de-Araujo, A., Vilegas, W., Colus, I.M., Varanda, E.A., 2010. Assessment of DNA damage induced by extracts, fractions and isolated compounds of *Davilla nitida* and *Davilla elliptica* (Dilleniaceae). *Mutation research* 702(1), 92-99.
- Carlos, I., Lopes, F., Benzatti, F., Carli, C., Marques, M.F., Jordão Junior, C.M., Rinaldo, D., Calvo, T.R., Santos, L.C., Vilegas, W., 2005. Ação do extrato metanólico e etanólico de *Davilla elliptica* St. Hill.(Malpighiaceae) na resposta imune.
- Cordido, F., Garcia-Mayor, R.V., Larranaga, A., 2014. Obesity, adipose tissue, inflammation and update on obesity management. *Obes Control Ther* 1(2), 1-8.
- Campos, J.J., Azevedo Ade, O., Filho, J.D., Perez, A.C., Braga, F.C., 2013. Bioguided isolation of myricetin-3-O-beta-galactopyranoside with antinociceptive activity from the aerial part of *Davilla elliptica* St.-Hil. *Journal of ethnopharmacology* 150(1), 270-274.
- Chang, C.J., Tzeng, T.F., Liou, S.S., Chang, Y.S., Liu, I.M., 2012. Myricetin Increases Hepatic Peroxisome Proliferator-Activated Receptor alpha Protein Expression and Decreases Plasma Lipids and Adiposity in Rats. *Evidence-based complementary and alternative medicine : eCAM* 2012, 787152.
- Despres, J.P., Lemieux, I., 2006. Abdominal obesity and metabolic syndrome. *Nature* 444(7121), 881-887.
- Fu, C., Jiang, Y., Guo, J., Su, Z., 2016. Natural Products with Anti-obesity Effects and Different Mechanisms of Action. *Journal of agricultural and food chemistry* 64(51), 9571-9585.
- Guaraldo, L., Sertie, J.A., Bacchi, E.M., 2001. Antiulcer action of the hydroalcoholic extract and fractions of *Davilla rugosa* Poiret in the rat. *Journal of ethnopharmacology* 76(2), 191-195.
- Guruvaiah, P., Guo, H., Li, D., Xie, Z., 2018. Preventive Effect of Flavonol Derivatives Abundant Sanglan Tea on Long-Term High-Fat-Diet-Induced Obesity Complications in C57BL/6 Mice. *Nutrients* 10(9).
- Hill, J.O., Melanson, E.L., Wyatt, H.T., 2000. Dietary fat intake and regulation of energy balance: implications for obesity. *The Journal of nutrition* 130(2S Suppl), 284S-288S.
- Hoek-van den Hil, E.F., Keijer, J., Bunschoten, A., Vervoort, J.J., Stankova, B., Bekkenkamp, M., Herreman, L., Venema, D., Hollman, P.C., Tvrzicka, E., Rietjens, I.M., van Schothorst,

- E.M., 2013. Quercetin induces hepatic lipid omega-oxidation and lowers serum lipid levels in mice. *PloS one* 8(1), e51588.
- Hu, T., Yuan, X., Wei, G., Luo, H., Lee, H.J., Jin, W., 2018. Myricetin-induced brown adipose tissue activation prevents obesity and insulin resistance in db/db mice. *European journal of nutrition* 57(1), 391-403.
- Jácome, R., Oliveira, V.D.C., Oliveira, M.A.T., Mariano, M.C.F., Oliveira, A.B.d., 2010. Estudo farmacognóstico comparativo das folhas de *Davilla elliptica* A. St.-Hil. e *D. rugosa* Poir., Dilleniaceae. *Revista Brasileira de Farmacognosia* 20, 390-396.
- Kim, N.H., Heo, J.D., Rho, J.R., Yang, M.H., Jeong, E.J., 2017. Anti-obesity Effect of Halophyte Crop, *Limonium tetragonum* in High-Fat Diet-Induced Obese Mice and 3T3-L1 Adipocytes. *Biological & pharmaceutical bulletin* 40(11), 1856-1865.
- Kuipers, E.N., Dam, A.D.V., Held, N.M., Mol, I.M., Houtkooper, R.H., Rensen, P.C.N., Boon, M.R., 2018. Quercetin Lowers Plasma Triglycerides Accompanied by White Adipose Tissue Browning in Diet-Induced Obese Mice. *International journal of molecular sciences* 19(6).
- Lee, S.G., Lee, Y.J., Jang, M.H., Kwon, T.R., Nam, J.O., 2017. *Panax ginseng* Leaf Extracts Exert Anti-Obesity Effects in High-Fat Diet-Induced Obese Rats. *Nutrients* 9(9).
- Michelin, D., Iha, S., Rinaldo, D., Sannomiya, M., Santos, L.C.d., Vilegas, W., Salgado, H.R.N., 2005. Antimicrobial activity of *Davilla elliptica* St. Hill (Dilleniaceae). *Revista Brasileira de Farmacognosia* 15(3), 209-211.
- Marcela M. R. Aguiar, Kamylla T. Santos, Vanessa A. Royo, Francine S. A. da Fonseca, Elytania V. Menezes, Maria O. Mercadante-Simões, Dario A. de Oliveira, Afrânio Farias de Melo Júnior, 2015. Antioxidant activity, total flavonoids and volatile constituents of *Magonia Pubescens* A.St.-Hil. *Journal of Medicinal Plants Research* 9, 1089- 1097.
- Oliveira, V., Ferreira, A., Chaves de Oliveira, M., M. Teixeira d, M., G.L. Brandão, M., 2014. Effects of *Xylopiá aromática* (Lam.) Mart. fruit on metabolic and inflammatory dysfunction induced by high refined carbohydrate-containing-diet in mice.
- Ong, K.C., Khoo, H.E., 1997. Biological effects of myricetin. *General pharmacology* 29(2), 121-126.
- Panche, A. N.; Diwan, A. D., Chandra, S. R., 2016. Flavonoids: an overview. *Journal of nutritional science*, (5).
- Rodrigues, Luciene, Antônio De Carvalho, Douglas, Jane Gomes, Laura, Botrel, Rejane, 2002. Espécies vegetais nativas usadas pela população local em Luminárias, MG1.
- Rodrigues, C.M., Rinaldo, D., Sannomiya, M., dos Santos, L.C., Montoro, P., Piacente, S., Pizza, C., Vilegas, W., 2008. High-performance liquid chromatographic separation and identification of polyphenolic compounds from the infusion of *Davilla elliptica* St. Hill. *Phytochemical analysis : PCA* 19(1), 17-24.

- Rodrigues, V. E.G., Carvalho, 2001. Levantamento etnobotânico de plantas medicinais no domínio do Cerrado na região do Alto Rio Grande: Minas Gerais. *Cienc Agrotec.*, 102-123.
- Rotta, E., Beltrami, L., Zonta, M., 2008. Manual de prática de coleta e herborização de material botânico. Embrapa Florestas: Colombo, Brazil.
- Soares, M., H. Rezende, M., D. Ferreira, H., D. L. Figueiredo, A., G. L. Bustamante, K., Bara, M., Paula, J., 2005. Caracterização farmacognóstica de folhas de *Davilla elliptica* St.-Hil. (Dilleniaceae).
- Sahebkar, A., 2017. Effects of quercetin supplementation on lipid profile: A systematic review and meta-analysis of randomized controlled trials. *Critical reviews in food science and nutrition* 57(4), 666-676.
- Seeram, N.P., Adams, L.S., Hardy, M.L., Heber, D., 2004. Total cranberry extract versus its phytochemical constituents: antiproliferative and synergistic effects against human tumor cell lines. *Journal of agricultural and food chemistry* 52(9), 2512-2517.
- Seyedan, A., Alshawsh, M.A., Alshagga, M.A., Koosha, S., Mohamed, Z., 2015. Medicinal Plants and Their Inhibitory Activities against Pancreatic Lipase: A Review. *Evidence-based complementary and alternative medicine : eCAM* 2015, 973143.
- Shao, L., Liu, K., Huang, F., Guo, X., Wang, M., Liu, B., 2013. Opposite effects of quercetin, luteolin, and epigallocatechin gallate on insulin sensitivity under normal and inflammatory conditions in mice. *Inflammation* 36(1), 1-14.
- Srinivasan, P., Vijayakumar, S., Kothandaraman, S., Palani, M., 2018. Anti-diabetic activity of quercetin extracted from *Phyllanthus emblica* L. fruit: In silico and in vivo approaches. *Journal of pharmaceutical analysis* 8(2), 109-118.
- Veg Rodrigues, Da Carvalho, Veg Rodrigues, Carvalho, D., 2001. Levantamento etnobotânico de plantas medicinais no domínio do cerrado na região do Alto Rio Grande: Minas Gerais. *Cienc Agrotec.*, 102-123.
- World Health Organization, (WHO), 2018. Obesity and overweight. Retrieved from: <https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight>.
- White, P.A., Cercato, L.M., Batista, V.S., Camargo, E.A., De Lucca, W., Jr., Oliveira, A.S., Silva, F.T., Goes, T.C., Oliveira, E.R., Moraes, V.R., Nogueira, P.C., De Oliveira, E.S.A.M., Quintans-Junior, L.J., Lima, B.S., Araujo, A.A., Santos, M.R., 2016. Aqueous extract of *Chrysobalanus icaco* leaves, in lower doses, prevent fat gain in obese high-fat fed mice. *Journal of ethnopharmacology* 179, 92-100.

## 6 CONCLUSÕES

Com base no levantamento científico realizado através da revisão de literatura, é possível concluir que a *D. elliptica* exerce efeitos benéficos sobre inflamação, modulando genes associados a esse processo, como TNF- $\alpha$ , COX-1. Além disso, apresenta efeitos gastroprotetores, aumentando a biodisponibilidade da glutatona de modo a atuar como sistema de defesa antioxidante.

Fundamentado nas investigações experimentais realizadas até o momento, conclui-se que a *D. elliptica* reduz adiposidade em animais obesos induzidos por dieta e melhora parâmetros bioquímicos, triglicérides e colesterol total, em animais alimentados com dieta padrão, exercendo possíveis efeitos sobre vias moleculares ainda não elucidadas.

Em conjunto, esses achados apontam a *D. elliptica*, como possível agente antiobesidade, novos estudos serão necessários para explicar o mecanismo molecular envolvido nos efeitos observados, permitindo que a *D. elliptica*, futuramente, possa ser utilizada como um medicamento para o tratamento de doenças e abra a perspectiva de desenvolvimento de novos medicamentos.

## REFERÊNCIAS

1. Fruh SM. Obesity: Risk factors, complications, and strategies for sustainable long-term weight management. *Journal of the American Association of Nurse Practitioners*. 2017 Oct;29(S1):S3-S14. PubMed PMID: 29024553. Pubmed Central PMCID: 6088226.
2. Berrington de Gonzalez A, Hartge P, Cerhan JR, Flint AJ, Hannan L, MacInnis RJ, et al. Body-mass index and mortality among 1.46 million white adults. *The New England journal of medicine*. 2010 Dec 2;363(23):2211-9. PubMed PMID: 21121834. Pubmed Central PMCID: 3066051.
3. Kuk JL, Ardern CI, Church TS, Sharma AM, Padwal R, Sui X, et al. Edmonton Obesity Staging System: association with weight history and mortality risk. *Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme*. 2011 Aug;36(4):570-6. PubMed PMID: 21838602.
4. Fu C, Jiang Y, Guo J, Su Z. Natural Products with Anti-obesity Effects and Different Mechanisms of Action. *Journal of agricultural and food chemistry*. 2016 Dec 28;64(51):9571-85. PubMed PMID: 27931098.
5. Bhurosy T, Jeewon R. Overweight and obesity epidemic in developing countries: a problem with diet, physical activity, or socioeconomic status? *The Scientific World Journal*. 2014;964236. PubMed PMID: 25379554. Pubmed Central PMCID: 4212551.
6. Wensveen FM, Valentic S, Sestan M, Turk Wensveen T, Polic B. The "Big Bang" in obese fat: Events initiating obesity-induced adipose tissue inflammation. *European journal of immunology*. 2015 Sep;45(9):2446-56. PubMed PMID: 26220361.
7. Kusminski CM, Bickel PE, Scherer PE. Targeting adipose tissue in the treatment of obesity-associated diabetes. *Nature reviews Drug discovery*. 2016 Sep;15(9):639-60. PubMed PMID: 27256476.
8. Scherer PE. Adipose tissue: from lipid storage compartment to endocrine organ. *Diabetes*. 2006 Jun;55(6):1537-45. PubMed PMID: 16731815.
9. Sun K, Kusminski CM, Scherer PE. Adipose tissue remodeling and obesity. *The Journal of clinical investigation*. 2011 Jun;121(6):2094-101. PubMed PMID: 21633177. Pubmed Central PMCID: 3104761.
10. Hursting SD, Dunlap SM. Obesity, metabolic dysregulation, and cancer: a growing concern and an inflammatory (and microenvironmental) issue. *Annals of the New York Academy of Sciences*. 2012 Oct;1271:82-7. PubMed PMID: 23050968. Pubmed Central PMCID: 3485672.
11. Bartelt A, Heeren J. Adipose tissue browning and metabolic health. *Nature reviews Endocrinology*. 2014 Jan;10(1):24-36. PubMed PMID: 24146030.
12. Van Marken Lichtenbelt WD, Vanhommerig JW, Smulders NM, Drossaerts JM, Kemerink GJ, Bouvy ND, et al. Cold-activated brown adipose tissue in healthy men. *The New England journal of medicine*. 2009 Apr 9;360(15):1500-8. PubMed PMID: 19357405.
13. Virtanen KA, Lidell ME, Orava J, Heglind M, Westergren R, Niemi T, et al. Functional brown adipose tissue in healthy adults. *The New England journal of medicine*. 2009 Apr 9;360(15):1518-25. PubMed PMID: 19357407.
14. Yoneshiro T, Aita S, Matsushita M, Kameya T, Nakada K, Kawai Y, et al. Brown adipose tissue, whole-body energy expenditure, and thermogenesis in healthy adult men. *Obesity*. 2011 Jan;19(1):13-6. PubMed PMID: 20448535.
15. Ouellet V, Routhier-Labadie A, Bellemare W, Lakhil-Chaieb L, Turcotte E, Carpentier AC, et al. Outdoor temperature, age, sex, body mass index, and diabetic status determine the prevalence, mass, and glucose-uptake activity of <sup>18</sup>F-FDG-detected BAT in



- humans. *The Journal of clinical endocrinology and metabolism*. 2011 Jan;96(1):192-9. PubMed PMID: 20943785.
16. Van der Lans AA, Hoeks J, Brans B, Vijgen GH, Visser MG, Vosselman MJ, et al. Cold acclimation recruits human brown fat and increases nonshivering thermogenesis. *The Journal of clinical investigation*. 2013 Aug;123(8):3395-403. PubMed PMID: 23867626. Pubmed Central PMCID: 3726172.
  17. Yoneshiro T, Aita S, Matsushita M, Kayahara T, Kameya T, Kawai Y, et al. Recruited brown adipose tissue as an antiobesity agent in humans. *The Journal of clinical investigation*. 2013 Aug;123(8):3404-8. PubMed PMID: 23867622. Pubmed Central PMCID: 3726164.
  18. Strassburg BBN, Brooks T, Feltran-Barbieri R, Iribarrem A, Crouzeilles R, Loyola R, et al. Moment of truth for the Cerrado hotspot. *Nature ecology & evolution*. 2017 Mar 23;1(4):99. PubMed PMID: 28812670.
  19. Ruggiero PGC, Batalha MA, Pivello VR, Meirelles ST. Soil-vegetation relationships in cerrado (Brazilian savanna) and semideciduous forest, Southeastern Brazil. *Plant Ecology*. 2002;160(1):1-16.
  20. Bourliere F, Hadley M. Present-day savannas: an overview. *Ecosystems of the world*. 1983.
  21. Goodland R. A Physiognomic Analysis of the Cerrado' Vegetation of Central Brasil. *Journal of ecology* 59(2) · July 1971
  22. Mügge FL, Paula-Souza J, Melo JC, Brandão MG. Native plant species with economic value from Minas Gerais and Goiás: a discussion on the currentness of the data recovered by the French naturalist Auguste de Saint-Hilaire. *Horticultura Brasileira*. 2016;34(4):455-62.
  23. Toledo CE, Britta EA, Ceole LF, Silva ER, de Mello JC, Dias Filho BP, et al. Antimicrobial and cytotoxic activities of medicinal plants of the Brazilian cerrado, using Brazilian cachaca as extractor liquid. *Journal of ethnopharmacology*. 2011 Jan 27;133(2):420-5. PubMed PMID: 20951786.
  24. Rios JL, Recio MC. Medicinal plants and antimicrobial activity. *Journal of ethnopharmacology*. 2005 Aug 22;100(1-2):80-4. PubMed PMID: 15964727.
  25. Akerele O. WHO guidelines for the assessment of herbal medicines. *Fitoterapia*. 1992;63:99-104.
  26. Samantha Salomão C, Lima C, Fernandes K. Biochemical characterization of selected plant species from Brazilian Savannas. *Braz. arch. biol. technol.* [online]. 2004, vol.47, n.2, pp.253-259
  27. Kumar G, Loganathan K, Rao B. Hemolytic activity of Indian medicinal plants towards human erythrocytes: An in vitro study 2011. 5534-7 p.
  28. BRASIL, Ministério da Saúde. Política nacional de práticas integrativas e complementares no SUS - PNPIC-SUS: atitude de ampliação de acesso. Brasília: Ministério da Saúde, (Série B Textos Básicos de Saúde). 2006.
  29. Cardozo CML, Inada AC, Marcelino G, Figueiredo PS, Arakaki DG, Hiane PA, et al. Therapeutic Potential of Brazilian Cerrado Campomanesia Species on Metabolic Dysfunctions. *Molecules*. 2018 Sep 13;23(9). PubMed PMID: 30216974. Pubmed Central PMCID: 6225494.
  30. Kubitzki K. *Doliocarpus, Davilla* und verwandte gattungen (Dilleniaceae). *Mitt bot Staatssamml Munchen*. 1971;9:1-105.
  31. Fraga CN, Stehmann JR. Novidades taxonômicas para Dilleniaceae brasileiras/Taxonomic novelties to Brazilian Dilleniaceae. *Rodriguésia*. 2010:S1-S6.
  32. Fraga CN. Filogenia e revisão taxonômica de *Davilla* Vand.(dilleniaceae). 2012.
  33. Guaraldo L, Chagas DA, Konno AC, Korn GP, Pfiffer T, Nasello AG. Hydroalcoholic extract and fractions of *Davilla rugosa* Poiret: effects on spontaneous motor activity and

- elevated plus-maze behavior. *Journal of ethnopharmacology*. 2000 Sep;72(1-2):61-7. PubMed PMID: 10967455.
34. Guaraldo L, Sertie JA, Bacchi EM. Antiulcer action of the hydroalcoholic extract and fractions of *Davilla rugosa* Poiret in the rat. *Journal of ethnopharmacology*. 2001 Jul;76(2):191-5. PubMed PMID: 11390136.
35. Perim MC, Borges JDC, da Silva EML, Araujo TAS, da Silva ACO, da Silva VC, et al. In vitro antibacterial and time-kill assay of ethanolic extract of *Davilla nitida* bark on multidrug resistant bacteria isolated from diabetic foot lesions. *Natural product research*. 2018 Feb 23;1-6. PubMed PMID: 29475383.
36. Nascimento L, Rabelo S, Silva G, Nascimento F, Santos R. Biological Activity of *Davilla kunthii* A. St.–Hil.(Dilleniaceae). *Revista Brasileira de Plantas Mediciniais*. 2016;18(1):172-9.
37. David JM, Cruz FG, Guedes MLS, Chávez JP. Flavonol glycosides from *Davilla flexuosa*. *J Braz Chem Soc*. 1996;7(2):115-8.
38. Guaraldo L, Chagas DA, Konno AC, Korn GP, Pfiffer T, Nasello AG. Hydroalcoholic extract and fractions of *Davilla rugosa* Poiret: effects on spontaneous motor activity and elevated plus-maze behavior. *Journal of ethnopharmacology*. 2000 Sep;72(1-2):61-7. PubMed PMID: 10967455.
39. Guaraldo L, Sertie JA, Bacchi EM. Antiulcer action of the hydroalcoholic extract and fractions of *Davilla rugosa* Poiret in the rat. *Journal of ethnopharmacology*. 2001 Jul;76(2):191-5. PubMed PMID: 11390136.
40. David JM, Souza JdC, Guedes MLS, David JpDL. Estudo fitoquímico de *Davilla rugosa*: flavonóides e terpenóides. 2006 *Rev. bras. farmacogn*. [online]. Vol.16, n.1, pp.105-108.
41. Mendes FR, Tabach R, Carlini EA. Evaluation of *Baccharis trimera* and *Davilla rugosa* in tests for adaptogen activity. *Phytotherapy research : PTR*. 2007 Jun;21(6):517-22. PubMed PMID: 17326041.
42. Nascimento L, Rabelo S, Silva G, Nascimento F, Santos R. Biological Activity of *Davilla kunthii* A. St.–Hil.(Dilleniaceae). *Revista Brasileira de Plantas Mediciniais*. 2016;18(1):172-9.
43. Perim MC, Borges JDC, da Silva EML, Araujo TAS, da Silva ACO, da Silva VC, et al. In vitro antibacterial and time-kill assay of ethanolic extract of *Davilla nitida* bark on multidrug resistant bacteria isolated from diabetic foot lesions. *Natural product research*. 2018 Feb 23;1-6. PubMed PMID: 29475383.
44. Myers, N., Mittermeier, R.A., Mittermeier, C.G., da Fonseca, G.A.B., Kent, J., Biodiversity hotspots for conservation priorities. *Nature*. 2000.403(6772), 853.

## ANEXO

## ANEXO A – Parecer do Comitê de Ética e Pesquisa



UNIVERSIDADE ESTADUAL DE MONTES CLAROS  
 COMISSÃO DE ÉTICA EM EXPERIMENTAÇÃO  
 E BEM-ESTAR ANIMAL



PARECER CONSUBSTANCIADO

Montes Claros, 06 de setembro de 2018.

Processo N.º 164

Título do Projeto: Efeitos do extrato hidroalcoólico da folha de *Davilla elliptica* (Dilleniaceae) A. St.-Hil sobre parâmetros metabólicos de camundongos obesos induzidos por dieta  
Coordenador: Dr. Sérgio Henrique de Souza Santos

Histórico

A Organização Mundial de Saúde (OMS) aponta a obesidade como um dos mais importantes problemas de saúde pública. O potencial dos produtos naturais pode fornecer uma excelente estratégia na redução do ganho de peso. Os produtos naturais, incluindo extratos brutos e compostos isolados, induzem à redução do peso corporal e previnem a obesidade induzida pela dieta e doenças relacionadas. O Cerrado apresenta um importante bioma com espécies com potencial fitoterápico como a *Davilla elliptica*, descrita na literatura por seus efeitos anti-inflamatórios, antinociceptivo, antimicrobiano, gastroprotetor, gastro-hepatoprotetores, ação imunomoduladora e antitumoral. É válido o estudo do potencial terapêutico dessa planta dentro do contexto da obesidade. O presente projeto objetiva avaliar o potencial do extrato de folhas da *Davilla elliptica* na modulação da disfunção metabólica e inflamatória induzida em camundongos submetidos a uma dieta hiperlipídica.

Mérito

O experimento será realizado no biotério da UNIMONTES. Serão utilizados ao todo 64 camundongos, machos (entre 5-7 semanas) da linhagem *Swiss*, provenientes do Biotério do Centro de Ciências Biológicas e da Saúde (CCBS/ Unimontes). Durante as 8 primeiras semanas do experimento, os animais serão divididos em 2 grupos: dieta controle e dieta hiperlipídica. Após este período, todos os animais serão aleatoriamente separados em 8 grupos, contendo 8 animais/gaiola. Os grupos (G1 e G2) receberão as dietas padrão e hiperlipídica, respectivamente. O grupo (G3 e G6) receberá o extrato hidroalcoólico na dose de 5000 mg/kg<sup>(24)</sup> de peso corporal. Na mesma dose será administrada a fração alcaloídica (G4 e G7) e o pó das folhas pulverizadas (G5 e G8) da *D. elliptica*. Todos os animais serão tratados por um período de 30 dias. Ao final do tratamento, todos os animais, após jejum de 12 horas, serão eutanasiados por decapitação.

Parecer

Comissão de Ética em Experimentação e Bem-Estar Animal da Unimontes analisou o processo 164 e entende que o mesmo está dentro das normas da Comissão. Sendo assim, somos pela **APROVAÇÃO** do projeto de pesquisa.

*Prof. Orlando Raphael Lopes Jr.*

Comissão de Ética em Experimentação e Bem-Estar Animal da UNIMONTES

## ANEXO B – Autorização de coleta de material vegetal- SISBIO



Ministério do Meio Ambiente - MMA

Instituto Chico Mendes de Conservação da Biodiversidade - ICMBio

Sistema de Autorização e Informação em Biodiversidade - SISBIO

## Comprovante de registro para coleta de material botânico, fúngico e microbiológico

Número: 66693-1	Data da Emissão: 06/11/2018 16:54:26
-----------------	--------------------------------------

## Dados do titular

Nome: Sérgio Henrique Sousa Santos	CPF: 055.482.156-71
------------------------------------	---------------------

SISBIO

## Observações e ressalvas



1	O material biológico coletado deverá ser utilizado para atividades científicas ou didáticas no âmbito do ensino superior.
2	Este documento não abrange a coleta de vegetais hidróbios, tendo em vista que o Decreto-Lei nº 221/1967 e o Art. 36 da Lei nº 9.605/1998 estabelecem a necessidade de obtenção de autorização para coleta de vegetais hidróbios para fins científicos..
3	As atividades de campo exercidas por pessoa natural ou jurídica estrangeira, em todo o território nacional, que impliquem o deslocamento de recursos humanos e materiais, tendo por objeto coletar dados, materiais, espécimes biológicos e minerais, peças integrantes da cultura nativa e cultura popular, presente e passada, obtidos por meio de recursos e técnicas que se destinem ao estudo, à difusão ou à pesquisa, estão sujeitas a autorização do Ministério de Ciência e Tecnologia.
4	Esse documento não eximirá o pesquisador da necessidade de obter outras anuências, como: I) da comunidade indígena envolvida, ouvido o órgão indigenista oficial, quando as atividades de pesquisa forem executadas em terra indígena; II) do Conselho de Defesa Nacional, quando as atividades de pesquisa forem executadas em área indispensável à segurança nacional; III) da autoridade marítima, quando as atividades de pesquisa forem executadas em águas jurisdicionais brasileiras; IV) do Departamento Nacional da Produção Mineral, quando a pesquisa visar a exploração de depósitos fossilíferos ou a extração de espécimes fósseis; V) do órgão gestor da unidade de conservação estadual, distrital ou municipal, dentre outra
5	Este documento não é válido para: a) coleta ou transporte de espécies que constem nas listas oficiais de espécies ameaçadas de extinção; b) recebimento ou envio de material biológico ao exterior; e c) realização de pesquisa em unidade de conservação federal ou em caverna.
6	Este documento não dispensa o cumprimento da legislação que dispõe sobre acesso a componente do patrimônio genético existente no território nacional, na plataforma continental e na zona econômica exclusiva, ou ao conhecimento tradicional associado ao patrimônio genético, para fins de pesquisa científica, bioprospecção e desenvolvimento tecnológico. Veja maiores informações em <a href="http://www.mma.gov.br/cgen">www.mma.gov.br/cgen</a> .

## Táxons autorizados

#	Nível taxonômico	Táxon(s)
1	Espécie	Plantae > Angiospermae > Dicotyledoneae > Lythraceae > Lafaensia > Pacari
2	Espécie	Plantae > Magnoliophyta > Magnoliopsida > Dilleniales > Dilleniaceae > Davilla > Elliptica
3	Espécie	Plantae > Magnoliophyta > Magnoliopsida > Lamiales > Boraginaceae > Cordia > Verbenacea
4	Espécie	Plantae > Magnoliophyta > Magnoliopsida > Asterales > Asteraceae > Lychnophora > Ericoides



## ANEXO C – Autorização para pesquisa científica do estado de Minas Gerais

AUTORIZAÇÃO PARA PESQUISA CIENTÍFICA NO ESTADO DE MINAS GERAIS									
Número da Autorização			Data da Emissão			Prazo de Validade			
107/2017			29/12/2017			29/12/2018			
INFORMAÇÕES DO RESPONSÁVEL E DO PROJETO									
Título do Projeto	"Potencial terapêutico e farmacológico de espécies vegetais nativas da Bacia do Rio pandeiros no tratamento de doenças metabólicas: incentivo à preservação da flora".								
Instituição	Universidade Federal de Minas Gerais								
Responsável	Sergio Henrique Sousa Santos					CPF	055.482.156-71		
Logradouro	Rua Cosme e Damião								
Nº/KM	260	Complemento			Bairro/Localidade		Santo Expedito		
Município	Montes Claros			UF	MG	CEP	39401-502	Cx. Postal	
Telefone	(38) 2101-7710			Celular	(38) 99912-1055				
E-mail	sergiosousas@hotmail.com								
INTEGRANTES DA EQUIPE									
Nome		Instituição		CPF/RG		Função			
Alfredo Mauricio Batista de Paula		UFMG		860.835.869-49		Pesquisador Colaborador			
Bruna Mara Aparecida de Carvalho		UFMG		060.680.356-46		Pesquisadora Colaboradora			
Diego Vicente da Costa		UFMG		354.789.668-19		Pesquisador Colaborador			
Júlio Cota Silva		UFMG		067.256.616-88		Pesquisador Colaborador			
Igor viana Brandi		UFMG		814.462.926-49		Pesquisador Colaborador			
João Marcus Oliveira Andrade		UNIMONTES		081.794.126-60		Pesquisador Colaborador			
Janaina Ribeiro Oliveira		UNIMONTES		068.789.696-70		Colaboradora			
Amanda Souto Machado		UNIMONTES		103.743.826-46		Colaborador			
Deborah de Faria Lelis		UNIMONTES		108.815.546-42		Colaborador			
Daniela Fernanda de Freitas		UNIMONTES		053.384.946-20		Colaboradora			
Daniel Silva Moraes		UNIMONTES		098.038.796-50		Colaborador			
Luis Paulo Oliveira		UNIMONTES		080.724.386-89		Colaborador			
Natália Gonçalves Ribeiro		UNIMONTES		100.329.536-31		Colaboradora			
Jacira Neves Sousa		UNIMONTES		047.078.015-01		Colaboradora			
Victor Hugo Dantas Guimarães		UNIMONTES		116.318.186-27		Colaborador			
Fernanda Lopes Ferreira		UFMG		121.465.316-22		Colaborador			
Fábio Ribeiro dos Santos		UFMG		108.799.876-00		Colaborador			
INFORMAÇÕES DAS ATIVIDADES									
Tipo de Atividade:	<input type="checkbox"/> Captura		<input checked="" type="checkbox"/> Coleta		<input checked="" type="checkbox"/> Transporte		<input type="checkbox"/> Sem Coleta/Captura		
	<input type="checkbox"/> Abiótica	<input type="checkbox"/> Microrganismos	<input type="checkbox"/> Fungo	<input checked="" type="checkbox"/> Botânica	<input type="checkbox"/> Invertebrados				
	<input type="checkbox"/> Anfíbios	<input type="checkbox"/> Répteis	<input type="checkbox"/> Aves	<input type="checkbox"/> Mamíferos	<input type="checkbox"/> Ictiofauna				
OBSERVAÇÕES	Esta autorização permite coleta/transporte botânico de sementes, folhas e ramos das espécies citadas na tabela de estimativa de coleta. Esta autorização não permite coleta de espécies ameaçadas. Esta autorização permite até cinco (05) integrantes da equipe a cada campanha.								
LOCAL DA ATIVIDADE - EM UNIDADE DE CONSERVAÇÃO ESTADUAL									
Unidade de Conservação	Responsável pela UC	Contato (Telefone e e-mail)			Endereço da UC		Assinatura do Responsável pela UC		
Assinatura do responsável pela Autorização					Número do Processo SIGED/SIPRO - IEF/DFAU/GPROP				
 Janaina A. B. Aguiar Gerente de Projetos e Pesquisas do IEF Masp: 1131566-0					SIGED  00000241 2101 2018				
Cidade Administrativa Tancredo Neves, Edifício Minas - Gerência de Projetos e Pesquisas - 1º and. Rodovia João Paulo II, 4143, Bairro Serra Verde - CEP 31630-900 Telefones: (31) 3915-1328 E-mail: pesquisa.gprop@inssambiente.mg.gov.br									





**GOVERNO DO ESTADO DE MINAS GERAIS**  
SECRETARIA DE ESTADO DE MEIO AMBIENTE E DESENVOLVIMENTO SUSTENTÁVEL  
INSTITUTO ESTADUAL DE FLORESTAS  
DIRETORIA DE PROTEÇÃO À FAUNA  
GERÊNCIA DE PROJETOS E PESQUISAS

Refúgio de Vida Silvestre Estadual do Rio Pandeiros	Neilton Viana Neves	(38) 3621-0100 neilton.viana@meioambiente.mg.gov.br	BR 479, Vila da CEMIG, S/nº Distrito de Pandeiros. CEP: 39.490-000
APA Estadual do Rio Pandeiros	Altenfelder Martins da Fonseca	(38) 3625-6222 (38) 3625-6205 altenfelder.fonseca@meioambiente.mg.gov.br	Rua Joaquim Borges Monteiro nº 180 - Bonito de Minas CEP: 39.490-000

Esta autorização será válida apenas com a autenticação do responsável pela(s) Unidade(s) de Conservação.

**LOCAL DA ATIVIDADE - FORA DE UNIDADE DE CONSERVAÇÃO ESTADUAL (apenas para material botânico)**

Município(s) Não se aplica

**TRANSPORTE - DESTINO DO MATERIAL COLETADO**

Instituição(ões) ICA - UFMG  
Endereço(s) Montes Claros - MG

**Outras Observações e Ressalvas:**

- Esta autorização não exige o pesquisador titular e os membros de sua equipe da necessidade de obter as anuências previstas em outros instrumentos legais, bem como do consentimento do responsável pela área, pública ou privada, onde será realizada a atividade, inclusive do órgão gestor de terra indígena, da unidade de conservação federal, distrital ou municipal, ou do proprietário, arrendatário, posseiro ou morador de área dentro dos limites de unidade de conservação estadual cujo processo de regularização fundiária encontra-se em curso;
- O pesquisador titular deverá contatar a administração dessa unidade a fim de CONFIRMAR AS DATAS das expedições, as condições para realização das coletas e de uso da infraestrutura da unidade de conservação, quando for o caso;
- O Instituto Estadual de Florestas não se responsabiliza por qualquer dano a equipamentos, acidentes ou lesões físicas ou psíquicas, estando ainda, o pesquisador responsável e sua equipe ciente da vulnerabilidade da área de realização da pesquisa;
- O material biológico coletado deverá ser utilizado para atividades científicas ou didáticas no âmbito do ensino superior.
- O titular da autorização e os membros de sua equipe deverão optar por métodos de coleta e instrumentos de captura direcionados, sempre que possível ao grupo taxonômico de interesse, evitando a morte ou dano significativo a outros grupos e empregar esforços de coleta ou captura que não comprometa a viabilidade de populações do grupo taxonômico de interesse em condições *in situ*, quando for o caso;
- Esta autorização não permite captura/coleta/transporte:
  - para fins comerciais, industriais ou esportivos;
  - para realização de atividades integrantes do processo de licenciamento ambiental de empreendimentos, conforme resolução do CONAMA de nº 237 de 19/12/97, salvo quando especificado;
  - de espécies ameaçadas de extinção em lista oficial estadual, salvo quando constante de projeto específico autorizado pelo SISBIO;
  - de espécies ameaçadas de extinção em lista oficial federal, salvo quando constante de projeto específico autorizado pelo IEF;
  - de fauna e flora em áreas de domínio privado, sem o consentimento expresso ou tácito do proprietário nos termos do Código Civil;
- Esta autorização não permite transporte interestadual e internacional de material biológico;
- Esta autorização não dispensa o cumprimento da legislação que dispõe sobre o acesso ao patrimônio genético, sobre a proteção e o acesso ao conhecimento tradicional associado e sobre a repartição de benefícios para conservação e uso sustentável da biodiversidade. Veja maiores informações em [www.mma.gov.br](http://www.mma.gov.br);
- O titular desta autorização, assim como os membros de sua equipe, quando da violação da legislação vigente, ou quando da inadequação, omissão ou falsa descrição de informações relevantes que subsidiaram a expedição do ato, poderá, mediante decisão motivada, ter a autorização suspensa ou revogada pelo IEF e o material biológico coletado apreendido nos termos da legislação em vigor;
- O responsável poderá, durante a validade desta autorização e conforme Termo de Compromisso firmado, solicitar à Gerência de Projeto e Pesquisas do IEF Renovação, Cancelamento ou Conclusão, conforme instruções no site do IEF (<http://www.ief.mg.gov.br/biodiversidade/pesquisa-cientifica>);
- Esta autorização é válida somente sem emendas ou rasuras e exclusivamente no estado de Minas Gerais;
- O pesquisador deverá estar sempre acompanhado desta autorização para apresentá-la às autoridades, quando solicitado.

Assinatura do responsável pela Autorização

*Janaina A. B. Aguiar*  
Gerente de Projetos e Pesquisas do IEF  
Masp: 1131586-0

Número do Processo SIGED/SIPRO - IEF/DFAU/GPROP

ANEXO D- Normas para publicação no periódico *Journal of Ethnopharmacology*

## JOURNAL OF ETHNOPHARMACOLOGY

### GUIDE FOR AUTHORS

#### INTRODUCTION

The Journal of Ethnopharmacology is dedicated to the exchange of information and understandings about people's use of plants, fungi, animals, microorganisms and minerals and their biological and pharmacological effects based on the principles established through international conventions. Early people, confronted with illness and disease, discovered a wealth of useful therapeutic agents in the plant and animal kingdoms. The empirical knowledge of these medicinal substances and their toxic potential was passed on by oral tradition and sometimes recorded in herbals and other texts on materia medica. Many valuable drugs of today (e.g., atropine, ephedrine, tubocurarine, digoxin, reserpine) came into use through the study of indigenous remedies. Chemists continue to use plant-derived drugs (e.g., morphine, taxol, physostigmine, quinidine, emetine) as prototypes in their attempts to develop more effective and less toxic medicinals.

**Please note that figures and tables should be embedded in the text as close as possible to where they are initially cited.** It is also mandatory to upload separate graphic and table files as these will be required if your manuscript is accepted for publication.

#### Classification of your paper

Please note that upon submitting your article you will have to select **at least one classification and at least three of the given keywords**. You can preview the list of classifications and keywords ([here](#)). This information is needed by the Editors to more quickly process your article. In addition to this, you can submit free keywords as described below under "Keywords".

#### The "rules of 5"

The Editors and Editorial Board have developed the "Rules of 5" for publishing in JEP. We have produced five clear criteria that each author needs to think about before submitting a manuscript and setting the whole process of editing and reviewing at work. [Click here](#).

For more details on how to write a world class paper, please visit our Pharmacology Author Resources page.

**Authors are encouraged to submit video material or animation sequences** to support and enhance your scientific research. For more information please see the paragraph on video data below.

#### Types of paper

The Journal of Ethnopharmacology will accept the following contributions:

1. Original research articles - whose length is not limited and should include Title, Abstract, Methods and Materials, Results, Discussion, Conclusions, Acknowledgements and

References. As a guideline, a full length paper normally occupies no more than 10 printed pages of the journal, including tables and illustrations.

2. Short Communications - whose average length is not more than 4 pages in print (approx. 2000-2300 words, including abstract and references). A maximum of 2 illustrations (figures or tables) is allowed. See paragraph below for description and format.

3. Letters to the Editors.

4. Reviews - Authors intending to write review articles should consult and send an outline to the Reviews Editor (see inside front cover for contact information) before preparing their manuscripts. The organization and subdivision of review articles can be arranged at the author's discretion. Authors should keep in mind that a good review sets the trend and direction of future research on the subject matter being reviewed. Tables, figures and references are to be arranged in the same way as research articles in the journal. Reviews on topics that address cutting-edge problems are particularly welcome. Outlines for potential reviews need to include: A detailed abstract using the structure provided in the guidelines An annotated table of contents A short CV of the lead author

5. Book reviews - Books for review should be sent to the Reviews Editor.

6. Commentaries - invited, peer-reviewed, critical discussion about crucial aspects of the field but most importantly methodological and conceptual-theoretical developments in the field and should also provide a standard, for example, for pharmacological methods to be used in papers in the Journal of Ethnopharmacology. The scientific dialogue differs greatly in the social / cultural and natural sciences, the discussions about the common foundations of the field are ongoing and the papers published should contribute to a transdisciplinary and multidisciplinary discussion. The length should be a maximum of 2-3 printed pages or 2500 words. Please contact the Reviews Editor [j.ethnopharmacol@pharmacy.ac.uk](mailto:j.ethnopharmacol@pharmacy.ac.uk) with an outline.

7. Conference announcements and news.

### Submission checklist

Please click [here](#) to download the Submission **Checklist**. This is a mandatory file during submission. Upload the completed checklist and choose the file type as "Checklist".

You can use this list to carry out a final check of your submission before you send it to the journal for review. Please check the relevant section in this Guide for Authors for more details.

### Ensure that the following items are present:

One author has been designated as the corresponding author with contact details:

- E-mail address
- Full postal address

All necessary files have been uploaded:

*Manuscript:*

- Include keywords
- All figures (include relevant captions)
- All tables (including titles, description, footnotes)
- Ensure all figure and table citations in the text match the files provided
- Indicate clearly if color should be used for any figures in print

*Graphical Abstracts / Highlights files (where applicable)*

*Supplemental files (where applicable)*



Further considerations

- Manuscript has been 'spell checked' and 'grammar checked'
- All references mentioned in the Reference List are cited in the text, and vice versa
- Permission has been obtained for use of copyrighted material from other sources (including the Internet)
- Relevant declarations of interest have been made
- Journal policies detailed in this guide have been reviewed
- Referee suggestions and contact details provided, based on journal requirements

For further information, visit our [Support Center](#).

## **BEFORE YOU BEGIN**

### **Ethics in publishing**

Please see our information pages on [Ethics in publishing](#) and [Ethical guidelines for journal publication](#).

### **Policy and ethics**

In the covering letter, the author must also declare that the study was performed according to the international, national and institutional rules considering animal experiments, clinical studies and biodiversity rights. See below for further information. The ethnopharmacological importance of the study must also be explained in the cover letter.

**Animal and clinical studies** - Investigations using experimental animals must state in the Methods section that the research was conducted in accordance with the internationally accepted principles for laboratory animal use and care as found in for example the European Community guidelines (EEC Directive of 1986; 86/609/EEC) or the US guidelines (NIH publication #85-23, revised in 1985). Investigations with human subjects must state in the Methods section that the research followed guidelines of the Declaration of Helsinki and Tokyo for humans, and was approved by the institutional human experimentation committee or equivalent, and that informed consent was obtained. The Editors will reject papers if there is any doubt about the suitability of the animal or human procedures used.

**Biodiversity rights** - Each country has its own rights on its biodiversity. Consequently for studying plants one needs to follow the international, national and institutional rules concerning the biodiversity rights.

Author contributions

For each author the contribution to the publication should be mentioned.

### **Declaration of interest**

All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence (bias) their work. Examples of potential competing interests include employment, consultancies, stock ownership, honoraria, paid expert testimony, patent applications/registrations, and grants or other funding. Authors must disclose any interests in two places: 1. A summary declaration of interest statement in the title page file (if double-blind) or the manuscript file (if single-blind). If there are no interests to declare then please state this: 'Declarations of interest: none'. This summary statement will be ultimately published if the article is accepted.

2. Detailed disclosures as part of a separate Declaration of Interest form, which forms part of the journal's official records. It is important for potential interests to be declared in both places and that the information matches. [More information](#).

### **Submission declaration and verification**

Submission of an article implies that the work described has not been published previously (except in the form of an abstract, a published lecture or academic thesis, see '[Multiple, redundant or concurrent publication](#)' for more information), that it is not under consideration for publication elsewhere, that its publication is approved by all authors and tacitly or explicitly by the responsible authorities where the work was carried out, and that, if accepted, it will not be published elsewhere in the same form, in English or in any other language, including electronically without the written consent of the copyright holder. To verify originality, your article may be checked by the originality detection service [Crossref Similarity Check](#).

### **Preprints**

Please note that [preprints](#) can be shared anywhere at any time, in line with Elsevier's [sharing policy](#). Sharing your preprints e.g. on a preprint server will not count as prior publication (see '[Multiple, redundant or concurrent publication](#)' for more information).

### **Use of inclusive language**

Inclusive language acknowledges diversity, conveys respect to all people, is sensitive to differences, and promotes equal opportunities. Articles should make no assumptions about the beliefs or commitments of any reader, should contain nothing which might imply that one individual is superior to another on the grounds of race, sex, culture or any other characteristic, and should use inclusive language throughout. Authors should ensure that writing is free from bias, for instance by using 'he or she', 'his/her' instead of 'he' or 'his', and by making use of job titles that are free of stereotyping (e.g. 'chairperson' instead of 'chairman' and 'flight attendant' instead of 'stewardess').

### **Changes to authorship**

Authors are expected to consider carefully the list and order of authors **before** submitting their manuscript and provide the definitive list of authors at the time of the original submission. Any addition, deletion or rearrangement of author names in the authorship list should be made only **before** the manuscript has been accepted and only if approved by the journal Editor. To request such a change, the Editor must receive the following from the **corresponding author**: (a) the reason for the change in author list and (b) written confirmation (e-mail, letter) from all authors that they agree with the addition, removal or rearrangement. In the case of addition or removal of authors, this includes confirmation from the author being added or removed. Only in exceptional circumstances will the Editor consider the addition, deletion or rearrangement of authors **after** the manuscript has been accepted. While the Editor considers the request, publication of the manuscript will be suspended. If the manuscript has already been published in an online issue, any requests approved by the Editor will result in a corrigendum.

### *Article transfer service*

This journal is part of our Article Transfer Service. This means that if the Editor feels your article is more suitable in one of our other participating journals, then you may be asked to consider transferring the article to one of those. If you agree, your article will be transferred

automatically on your behalf with no need to reformat. Please note that your article will be reviewed again by the new journal. [More information](#).

### **Copyright**

Upon acceptance of an article, authors will be asked to complete a 'Journal Publishing Agreement' (see [more information](#) on this). An e-mail will be sent to the corresponding author confirming receipt of the manuscript together with a 'Journal Publishing Agreement' form or a link to the online version of this agreement.

Subscribers may reproduce tables of contents or prepare lists of articles including abstracts for internal circulation within their institutions. [Permission](#) of the Publisher is required for resale or distribution outside the institution and for all other derivative works, including compilations and translations. If excerpts from other copyrighted works are included, the author(s) must obtain written permission from the copyright owners and credit the source(s) in the article. Elsevier has [preprinted forms](#) for use by authors in these cases.

For gold open access articles: Upon acceptance of an article, authors will be asked to complete an 'Exclusive License Agreement' ([more information](#)). Permitted third party reuse of gold open access articles is determined by the author's choice of [user license](#).

### **Author rights**

As an author you (or your employer or institution) have certain rights to reuse your work. [More information](#).

#### *Elsevier supports responsible sharing*

Find out how you can [share your research](#) published in Elsevier journals.

### **Role of the funding source**

You are requested to identify who provided financial support for the conduct of the research and/or preparation of the article and to briefly describe the role of the sponsor(s), if any, in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the article for publication. If the funding source(s) had no such involvement then this should be stated.

#### *Funding body agreements and policies*

Elsevier has established a number of agreements with funding bodies which allow authors to comply with their funder's open access policies. Some funding bodies will reimburse the author for the gold open access publication fee. Details of [existing agreements](#) are available online.

### **Open access**

This journal offers authors a choice in publishing their research:

#### **Subscription**

- Articles are made available to subscribers as well as developing countries and patient groups through our [universal access programs](#).
- No open access publication fee payable by authors.
- The Author is entitled to post the [accepted manuscript](#) in their institution's repository and make this public after an embargo period (known as green Open Access). The [published journal article](#) cannot be shared publicly, for example on ResearchGate or Academia.edu, to

ensure the sustainability of peerreviewed research in journal publications. The embargo period for this journal can be found below.

#### **Gold open access**

- Articles are freely available to both subscribers and the wider public with permitted reuse.
- A gold open access publication fee is payable by authors or on their behalf, e.g. by their research funder or institution.

Regardless of how you choose to publish your article, the journal will apply the same peer review criteria and acceptance standards.

For gold open access articles, permitted third party (re)use is defined by the following [Creative Commons user licenses](#):

#### *Creative Commons Attribution (CC BY)*

Lets others distribute and copy the article, create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), include in a collective work (such as an anthology), text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.

#### *Creative Commons Attribution-NonCommercial-NoDerivs (CC BY-NC-ND)*

For non-commercial purposes, lets others distribute and copy the article, and to include in a collective work (such as an anthology), as long as they credit the author(s) and provided they do not alter or modify the article.

The gold open access publication fee for this journal is **USD 3600**, excluding taxes. Learn more about Elsevier's pricing policy: <https://www.elsevier.com/openaccesspricing>.

#### *Green open access*

Authors can share their research in a variety of different ways and Elsevier has a number of green open access options available. We recommend authors see our [open access page](#) for further information. Authors can also self-archive their manuscripts immediately and enable public access from their institution's repository after an embargo period. This is the version that has been accepted for publication and which typically includes author-incorporated changes suggested during submission, peer review and in editor-author communications. Embargo period: For subscription articles, an appropriate amount of time is needed for journals to deliver value to subscribing customers before an article becomes freely available to the public. This is the embargo period and it begins from the date the article is formally published online in its final and fully citable form. [Find out more](#).

This journal has an embargo period of 12 months.

#### *Elsevier Researcher Academy*

[Researcher Academy](#) is a free e-learning platform designed to support early and mid-career researchers throughout their research journey. The "Learn" environment at Researcher Academy offers several interactive modules, webinars, downloadable guides and resources to guide you through the process of writing for research and going through peer review. Feel free to use these free resources to improve your submission and navigate the publication process with ease.

*Language (usage and editing services)*

Please write your text in good English (American or British usage is accepted, but not a mixture of these). Authors who feel their English language manuscript may require editing to eliminate possible grammatical or spelling errors and to conform to correct scientific English may wish to use the [English Language Editing service](#) available from Elsevier's WebShop.

**Submission**

Our online submission system guides you stepwise through the process of entering your article details and uploading your files. The system converts your article files to a single PDF file used in the peer-review process. Editable files (e.g., Word, LaTeX) are required to typeset your article for final publication. All correspondence, including notification of the Editor's decision and requests for revision, is sent by e-mail.

**Additional information**

Authors who want to submit a manuscript should consult and peruse carefully recent issues of the journal for format and style. Authors must include the following contact details on the title page of their submitted manuscript: full postal address; fax; e-mail. All manuscripts submitted are subject to peer review. The minimum requirements for a manuscript to qualify for peer review are that it has been prepared by strictly following the format and style of the journal as mentioned, that it is written in good English, and that it is complete. Manuscripts that have not fulfilled these requirements will be returned to the author(s).

In addition, you are recommended to adhere to the research standards described in the following articles:

Cos P., Vlietinck A.J., Berghe D.V., et al. (2006) Anti-infective potential of natural products: how to develop a stronger in vitro 'proof-of-concept'. *Journal of Ethnopharmacology*, 106: 290-302.

Matteucci, E., Giampietro, O. (2008) Proposal open for discussion: defining agreed diagnostic procedures in experimental diabetes research. *Journal of Ethnopharmacology*, 115: 163-172.

Froede, T.S.A. and Y.S. Medeiros, Y.S. (2008) Animal models to test drugs with potential antidiabetic activity. *Journal of Ethnopharmacology* 115: 173-183. Gertsch J. (2009) How scientific is the science in ethnopharmacology? Historical perspectives and epistemological problems. *Journal of Ethnopharmacology*, 122: 177-183.

Chan K., et al. (2012) Good practice in reviewing and publishing studies on herbal medicine, with special emphasis on traditional Chinese medicine and Chinese Materia Medica. *Journal of Ethnopharmacology* 140: 469-475.

Heinrich, M., Edwards. S., Moerman. D.E.. and Leonti. M. (2009), Ethnopharmacological field studies: a critical assessment of their conceptual basis and methods. *J. Ethnopharmacol*, 124: 1-17.

**PREPARATION*****Peer review***

This journal operates a single blind review process. All contributions will be initially assessed by the editor for suitability for the journal. Papers deemed suitable are then typically sent to a

minimum of two independent expert reviewers to assess the scientific quality of the paper. The Editor is responsible for the final decision regarding acceptance or rejection of articles. The Editor's decision is final. [More information on types of peer review.](#)

#### *Use of word processing software*

It is important that the file be saved in the native format of the word processor used. The text should be in single-column format. Keep the layout of the text as simple as possible. Most formatting codes will be removed and replaced on processing the article. In particular, do not use the word processor's options to justify text or to hyphenate words. However, do use bold face, italics, subscripts, superscripts etc. When preparing tables, if you are using a table grid, use only one grid for each individual table and not a grid for each row. If no grid is used, use tabs, not spaces, to align columns.

The electronic text should be prepared in a way very similar to that of conventional manuscripts (see also the [Guide to Publishing with Elsevier](#)). Note that source files of figures, tables and text graphics will be required whether or not you embed your figures in the text. See also the section on Electronic artwork.

To avoid unnecessary errors you are strongly advised to use the 'spell-check' and 'grammar-check' functions of your word processor.

### **Article structure**

#### *Subdivision - numbered sections*

Divide your article into clearly defined and numbered sections. Subsections should be numbered 1.1 (then 1.1.1, 1.1.2, ...), 1.2, etc. (the abstract is not included in section numbering). Use this numbering also for internal cross-referencing: do not just refer to 'the text'. Any subsection may be given a brief heading. Each heading should appear on its own separate line.

#### *Introduction*

State the objectives of the work and provide an adequate background, avoiding a detailed literature survey or a summary of the results.

#### *Material and methods*

Provide sufficient details to allow the work to be reproduced by an independent researcher. Methods that are already published should be summarized, and indicated by a reference. If quoting directly from a previously published method, use quotation marks and also cite the source. Any modifications to existing methods should also be described.

#### *Theory/calculation*

A Theory section should extend, not repeat, the background to the article already dealt with in the Introduction and lay the foundation for further work. In contrast, a Calculation section represents a practical development from a theoretical basis.

#### *Results*

Results should be clear and concise.

#### *Discussion*

This should explore the significance of the results of the work, not repeat them. A combined Results and Discussion section is often appropriate. Avoid extensive citations and discussion of published literature.



### *Conclusions*

The main conclusions of the study may be presented in a short Conclusions section, which may stand alone or form a subsection of a Discussion or Results and Discussion section.

### *Glossary*

Please supply, as a separate list, the definitions of field-specific terms used in your article.

### *Appendices*

If there is more than one appendix, they should be identified as A, B, etc. Formulae and equations in appendices should be given separate numbering: Eq. (A.1), Eq. (A.2), etc.; in a subsequent appendix, Eq. (B.1) and so on. Similarly for tables and figures: Table A.1; Fig. A.1, etc.

### **Essential title page information**

- **Title.** Concise and informative. Titles are often used in information-retrieval systems. Avoid abbreviations and formulae where possible.
- **Author names and affiliations.** Please clearly indicate the given name(s) and family name(s) of each author and check that all names are accurately spelled. You can add your name between parentheses in your own script behind the English transliteration. Present the authors' affiliation addresses (where the actual work was done) below the names. Indicate all affiliations with a lowercase superscript letter immediately after the author's name and in front of the appropriate address. Provide the full postal address of each affiliation, including the country name and, if available, the e-mail address of each author.
- **Corresponding author.** Clearly indicate who will handle correspondence at all stages of refereeing and publication, also post-publication. This responsibility includes answering any future queries about Methodology and Materials. **Ensure that the e-mail address is given and that contact details are kept up to date by the corresponding author.**
- **Present/permanent address.** If an author has moved since the work described in the article was done, or was visiting at the time, a 'Present address' (or 'Permanent address') may be indicated as a footnote to that author's name. The address at which the author actually did the work must be retained as the main, affiliation address. Superscript Arabic numerals are used for such footnotes.

### **Abstract**

A concise and factual abstract is required. The abstract should state briefly the purpose of the research, the principal results and major conclusions. An abstract is often presented separately from the article, so it must be able to stand alone. For this reason, References should be avoided, but if essential, then cite the author(s) and year(s). Also, non-standard or uncommon abbreviations should be avoided, but if essential they must be defined at their first mention in the abstract itself.

The author should divide the abstract with the **headings Ethnopharmacological relevance, Aim of the study, Materials and Methods, Results, and Conclusions.**

Click [here](#) to see an example.

### *Graphical abstract*

A graphical abstract is mandatory for this journal. It should summarize the contents of the article in a concise, pictorial form designed to capture the attention of a wide readership online. Authors must provide images that clearly represent the work described in the article.

Graphical abstracts should be submitted as a separate file in the online submission system. Image size: please provide an image with a minimum of 531 × 1328 pixels (h × w) or proportionally more. The image should be readable at a size of 5 × 13 cm using a regular screen resolution of 96 dpi. Preferred file types: TIFF, EPS, PDF or MS Office files. You can view [Example Graphical Abstracts](#) on our information site. Authors can make use of Elsevier's [Illustration Services](#) to ensure the best presentation of their images also in accordance with all technical requirements. Keywords After having selected a classification in the submission system, authors must in the same step select 5

#### *keywords.*

These keywords will help the Editors to categorize your article accurately and process it more quickly. A list of the classifications and set keywords can be found [here](#).

In addition, you can provide a maximum of 6 specific keywords, using American spelling and avoiding general and plural terms and multiple concepts (avoid, for example, "and", "of"). Be sparing with abbreviations: only abbreviations firmly established in the field may be eligible. These keywords will be used for indexing purposes.

#### *Plant names*

In the Materials and Methods section there must be a separate heading for describing the material used. That includes official name, local name, English name (if known), GPS position in case of collection in the wild or cultivation, a voucher specimen must be deposited in an official herbarium for possible future comparison. In the text it should be stated that the plant name has been checked with <http://www.theplantlist.org> mentioning the data of accessing that website. In case of commercially procured material should mention the source, batch number, quality control data. Data on chemical characterization (metabolomics, chromatographic methods) should also be presented, in case of known active compounds their quantitative analysis should be presented.

#### *Acknowledgements*

Collate acknowledgements in a separate section at the end of the article before the references and do not, therefore, include them on the title page, as a footnote to the title or otherwise. List here those individuals who provided help during the research (e.g., providing language help, writing assistance or proof reading the article, etc.).

#### *Formatting of funding sources*

List funding sources in this standard way to facilitate compliance to funder's requirements:

Funding: This work was supported by the National Institutes of Health [grant numbers xxxx, yyyy]; the Bill & Melinda Gates Foundation, Seattle, WA [grant number zzzz]; and the United States Institutes of Peace [grant number aaaa].

It is not necessary to include detailed descriptions on the program or type of grants and awards. When funding is from a block grant or other resources available to a university, college, or other research institution, submit the name of the institute or organization that provided the funding.

If no funding has been provided for the research, please include the following sentence:



This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

### *Math formulae*

Please submit math equations as editable text and not as images. Present simple formulae in line with normal text where possible and use the solidus (/) instead of a horizontal line for small fractional terms, e.g., X/Y. In principle, variables are to be presented in italics. Powers of e are often more conveniently denoted by exp. Number consecutively any equations that have to be displayed separately from the text (if referred to explicitly in the text).

### *Footnotes*

Footnotes should be used sparingly. Number them consecutively throughout the article. Many word processors can build footnotes into the text, and this feature may be used. Otherwise, please indicate the position of footnotes in the text and list the footnotes themselves separately at the end of the article. Do not include footnotes in the Reference list.

## **Artwork**

Electronic artwork

General points

- Make sure you use uniform lettering and sizing of your original artwork.
- Embed the used fonts if the application provides that option.
- Aim to use the following fonts in your illustrations: Arial, Courier, Times New Roman, Symbol, or use fonts that look similar.
- Number the illustrations according to their sequence in the text.
- Use a logical naming convention for your artwork files.
- Provide captions to illustrations separately.
- Size the illustrations close to the desired dimensions of the published version.
- Submit each illustration as a separate file.

A detailed guide on [electronic artwork](#) is available.

**You are urged to visit this site; some excerpts from the detailed information are given here.**

Formats

If your electronic artwork is created in a Microsoft Office application (Word, PowerPoint, Excel) then please supply 'as is' in the native document format.

Regardless of the application used other than Microsoft Office, when your electronic artwork is finalized, please 'Save as' or convert the images to one of the following formats (note the resolution requirements for line drawings, halftones, and line/halftone combinations given below):

EPS (or PDF): Vector drawings, embed all used fonts.

TIFF (or JPEG): Color or grayscale photographs (halftones), keep to a minimum of 300 dpi.

TIFF (or JPEG): Bitmapped (pure black & white pixels) line drawings, keep to a minimum of 1000 dpi.

TIFF (or JPEG): Combinations bitmapped line/half-tone (color or grayscale), keep to a minimum of 500 dpi.

### **Please do not:**

- Supply files that are optimized for screen use (e.g., GIF, BMP, PICT, WPG); these typically have a low number of pixels and limited set of colors;
- Supply files that are too low in resolution;
- Submit graphics that are disproportionately large for the content.

Please note that figures and tables should be embedded in the text as close as possible to where they are initially cited. It is also mandatory to upload separate graphic and table files as these will be required if your manuscript is accepted for publication.

#### *Color artwork*

Please make sure that artwork files are in an acceptable format (TIFF (or JPEG), EPS (or PDF), or MS Office files) and with the correct resolution. If, together with your accepted article, you submit usable color figures then Elsevier will ensure, at no additional charge, that these figures will appear in color online (e.g., ScienceDirect and other sites) regardless of whether or not these illustrations are reproduced in color in the printed version. **For color reproduction in print, you will receive information regarding the costs from Elsevier after receipt of your accepted article.** Please indicate your preference for color: in print or online only. [Further information on the preparation of electronic artwork.](#)

#### *Figure captions*

Ensure that each illustration has a caption. Supply captions separately, not attached to the figure. A caption should comprise a brief title (**not** on the figure itself) and a description of the illustration. Keep text in the illustrations themselves to a minimum but explain all symbols and abbreviations used.

#### **Tables**

Please submit tables as editable text and not as images. Tables can be placed either next to the relevant text in the article, or on separate page(s) at the end. Number tables consecutively in accordance with their appearance in the text and place any table notes below the table body. Be sparing in the use of tables and ensure that the data presented in them do not duplicate results described elsewhere in the article. Please avoid using vertical rules and shading in table cells.

#### **References**

##### *Citation in text*

Please ensure that every reference cited in the text is also present in the reference list (and vice versa). Any references cited in the abstract must be given in full. Unpublished results and personal communications are not recommended in the reference list, but may be mentioned in the text. If these references are included in the reference list they should follow the standard reference style of the journal and should include a substitution of the publication date with "Unpublished results". "Personal communication" will not be accepted as a reference. Citation of a reference as "in press" implies that the item has been accepted for publication.

##### *Reference links*

Increased discoverability of research and high quality peer review are ensured by online links to the sources cited. In order to allow us to create links to abstracting and indexing services, such as Scopus, CrossRef and PubMed, please ensure that data provided in the references are correct. Please note that incorrect surnames, journal/book titles, publication year and pagination may prevent link creation. When copying references, please be careful as they may already contain errors. Use of the DOI is highly encouraged.

A DOI is guaranteed never to change, so you can use it as a permanent link to any electronic article. An example of a citation using DOI for an article not yet in an issue is: VanDecar J.C., Russo R.M., James D.E., Ambeh W.B., Franke M. (2003). Aseismic continuation of the

Lesser Antilles slab beneath northeastern Venezuela. *Journal of Geophysical Research*, <https://doi.org/10.1029/2001JB000884>. Please note the format of such citations should be in the same style as all other references in the paper.

#### *Data references*

This journal encourages you to cite underlying or relevant datasets in your manuscript by citing them in your text and including a data reference in your Reference List. Data references should include the following elements: author name(s), dataset title, data repository, version (where available), year, and global persistent identifier. Add [dataset] immediately before the reference so we can properly identify it as a data reference. The [dataset] identifier will not appear in your published article.

#### *Reference management software*

Most Elsevier journals have their reference template available in many of the most popular reference management software products. These include all products that support [Citation Style Language styles](#), such as [Mendeley](#). Using citation plug-ins from these products, authors only need to select the appropriate journal template when preparing their article, after which citations and bibliographies will be automatically formatted in the journal's style. If no template is yet available for this journal, please follow the format of the sample references and citations as shown in this Guide. If you use reference management software, please ensure that you remove all field codes before submitting the electronic manuscript. [More information on how to remove field codes from different reference management software](#).

Users of Mendeley Desktop can easily install the reference style for this journal by clicking the following link:

<http://open.mendeley.com/use-citation-style/journal-of-ethnopharmacology>

When preparing your manuscript, you will then be able to select this style using the Mendeley plugins for Microsoft Word or LibreOffice.

#### *Reference style*

##### *Text:*

All citations in the text should refer to:

1. Single author: the author's name (without initials, unless there is ambiguity) and the year of publication;
2. Two authors: both authors' names and the year of publication;
3. Three or more authors: first author's name followed by 'et al.' and the year of publication. Citations may be made directly (or parenthetically). Groups of references can be listed either first alphabetically, then chronologically, or vice versa.

Examples: 'as demonstrated (Allan, 2000a, 2000b, 1999; Allan and Jones, 1999).... Or, as demonstrated (Jones, 1999; Allan, 2000)... Kramer et al. (2010) have recently shown ...'

List: References should be arranged first alphabetically and then further sorted chronologically if necessary. More than one reference from the same author(s) in the same year must be identified by the letters 'a', 'b', 'c', etc., placed after the year of publication.

Examples:

##### *Reference to a journal publication:*

Van der Geer, J., Hanraads, J.A.J., Lupton, R.A., 2010. The art of writing a scientific article. *J. Sci. Commun.* 163, 51–59. <https://doi.org/10.1016/j.Sc.2010.00372>

##### *Reference to a journal publication with an article number:*

Van der Geer, J., Hanraads, J.A.J., Lupton, R.A., 2018. The art of writing a scientific article. *Heliyon.* 19, e00205. <https://doi.org/10.1016/j.heliyon.2018.e00205>

*Reference to a book:*

Strunk Jr., W., White, E.B., 2000. *The Elements of Style*, fourth ed. Longman, New York.

*Reference to a chapter in an edited book:*

Mettam, G.R., Adams, L.B., 2009. How to prepare an electronic version of your article, in: Jones, B.S., Smith, R.Z. (Eds.), *Introduction to the Electronic Age*. E-Publishing Inc., New York, pp. 281–304.

*Reference to a website:*

Cancer Research UK, 1975. Cancer statistics reports for the UK. <http://www.cancerresearchuk.org/aboutcancer/statistics/cancerstatsreport/> (accessed 13 March 2003).

*Reference to a dataset:*

[dataset] Oguro, M., Imahiro, S., Saito, S., Nakashizuka, T., 2015. Mortality data for Japanese oak wilt disease and surrounding forest compositions. *Mendeley Data*, v1. <https://doi.org/10.17632/xwj98nb39r.1>.

**Video**

Elsevier accepts video material and animation sequences to support and enhance your scientific research. Authors who have video or animation files that they wish to submit with their article are strongly encouraged to include links to these within the body of the article. This can be done in the same way as a figure or table by referring to the video or animation content and noting in the body text where it should be placed. All submitted files should be properly labeled so that they directly relate to the video file's content. In order to ensure that your video or animation material is directly usable, please provide the file in one of our recommended file formats with a preferred maximum size of 150 MB per file, 1 GB in total. Video and animation files supplied will be published online in the electronic version of your article in Elsevier Web products, including [ScienceDirect](#). Please supply 'stills' with your files: you can choose any frame from the video or animation or make a separate image. These will be used instead of standard icons and will personalize the link to your video data. For more detailed instructions please visit our [video instruction pages](#). Note: since video and animation cannot be embedded in the print version of the journal, please provide text for both the electronic and the print version for the portions of the article that refer to this content.

**Data visualization**

Include interactive data visualizations in your publication and let your readers interact and engage more closely with your research. Follow the instructions here to find out about available data visualization options and how to include them with your article.

**Supplementary material**

Supplementary material such as applications, images and sound clips, can be published with your article to enhance it. Submitted supplementary items are published exactly as they are received (Excel or PowerPoint files will appear as such online). Please submit your material together with the article and supply a concise, descriptive caption for each supplementary file. If you wish to make changes to supplementary material during any stage of the process, please make sure to provide an updated file. Do not annotate any corrections on a previous version. Please switch off the 'Track Changes' option in Microsoft Office files as these will appear in the published version.

**Research data**

This journal encourages and enables you to share data that supports your research publication where appropriate, and enables you to interlink the data with your published articles. Research

data refers to the results of observations or experimentation that validate research findings. To facilitate reproducibility and data reuse, this journal also encourages you to share your software, code, models, algorithms, protocols, methods and other useful materials related to the project.

Below are a number of ways in which you can associate data with your article or make a statement about the availability of your data when submitting your manuscript. If you are sharing data in one of these ways, you are encouraged to cite the data in your manuscript and reference list. Please refer to the "References" section for more information about data citation. For more information on depositing, sharing and using research data and other relevant research materials, visit the research data page.

#### *Data linking*

If you have made your research data available in a data repository, you can link your article directly to the dataset. Elsevier collaborates with a number of repositories to link articles on ScienceDirect with relevant repositories, giving readers access to underlying data that gives them a better understanding of the research described.

There are different ways to link your datasets to your article. When available, you can directly link your dataset to your article by providing the relevant information in the submission system. For more information, visit the [database linking page](#).

For [supported data repositories](#) a repository banner will automatically appear next to your published article on ScienceDirect.

In addition, you can link to relevant data or entities through identifiers within the text of your manuscript, using the following format: Database: xxxx (e.g., TAIR: AT1G01020; CCDC: 734053; PDB: 1XFN).

#### *Mendeley Data*

This journal supports Mendeley Data, enabling you to deposit any research data (including raw and processed data, video, code, software, algorithms, protocols, and methods) associated with your manuscript in a free-to-use, open access repository. During the submission process, after uploading your manuscript, you will have the opportunity to upload your relevant datasets directly to Mendeley Data. The datasets will be listed and directly accessible to readers next to your published article online.

For more information, visit the [Mendeley Data for journals page](#).

#### *Data in Brief*

You have the option of converting any or all parts of your supplementary or additional raw data into one or multiple data articles, a new kind of article that houses and describes your data. Data articles ensure that your data is actively reviewed, curated, formatted, indexed, given a DOI and publicly available to all upon publication. You are encouraged to submit your article for Data in Brief as an additional item directly alongside the revised version of your manuscript. If your research article is accepted, your data article will automatically be transferred over to Data in Brief where it will be editorially reviewed and published in the open access data journal, Data in Brief. Please note an open access fee of 500 USD is payable for publication in Data in Brief. Full details can be found on the [Data in Brief website](#). Please use [this template](#) to write your Data in Brief.

### *Data statement*

To foster transparency, we encourage you to state the availability of your data in your submission. This may be a requirement of your funding body or institution. If your data is unavailable to access or unsuitable to post, you will have the opportunity to indicate why during the submission process, for example by stating that the research data is confidential. The statement will appear with your published article on ScienceDirect. For more information, visit the [Data Statement page](#).

## **AFTER ACCEPTANCE**

### **Online proof correction**

Corresponding authors will receive an e-mail with a link to our online proofing system, allowing annotation and correction of proofs online. The environment is similar to MS Word: in addition to editing text, you can also comment on figures/tables and answer questions from the Copy Editor.

Web-based proofing provides a faster and less error-prone process by allowing you to directly type your corrections, eliminating the potential introduction of errors. If preferred, you can still choose to annotate and upload your edits on the PDF version. All instructions for proofing will be given in the e-mail we send to authors, including alternative methods to the online version and PDF.

We will do everything possible to get your article published quickly and accurately. Please use this proof only for checking the typesetting, editing, completeness and correctness of the text, tables and figures. Significant changes to the article as accepted for publication will only be considered at this stage with permission from the Editor. It is important to ensure that all corrections are sent back to us in one communication. Please check carefully before replying, as inclusion of any subsequent corrections cannot be guaranteed. Proofreading is solely your responsibility.

### **Offprints**

The corresponding author will, at no cost, receive a customized [Share Link](#) providing 50 days free access to the final published version of the article on [ScienceDirect](#). The Share Link can be used for sharing the article via any communication channel, including email and social media. For an extra charge, paper offprints can be ordered via the offprint order form which is sent once the article is accepted for publication. Both corresponding and co-authors may order offprints at any time via Elsevier's Webshop. Corresponding authors who have published their article gold open access do not receive a Share Link as their final published version of the article is available open access on ScienceDirect and can be shared through the article DOI link.

## **AUTHOR INQUIRIES**

Visit the [Elsevier Support Center](#) to find the answers you need. Here you will find everything from Frequently Asked Questions to ways to get in touch.

You can also [check the status of your submitted article](#) or find out [when your accepted article will be published](#).